# SUPPORTING MATERIAL FOR

# Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging

Zi Yao<sup>1,‡</sup>, Donald R. Caldwell<sup>4,‡</sup>, Anna C. Love<sup>1,‡</sup>, Bethany Kolbaba-Kartchner<sup>5,6</sup>, Jeremy H. Mills<sup>5,6</sup>, Martin J. Schnermann<sup>4,\*</sup>, Jennifer A. Prescher<sup>1,2,3,\*</sup>

Departments of <sup>1</sup>Chemistry, <sup>2</sup>Molecular Biology & Biochemistry, and <sup>3</sup>Pharmaceutical Sciences, University of California, Irvine, Irvine CA, United States

<sup>4</sup>Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick MD, United States

<sup>5</sup>School of Molecular Sciences, and <sup>6</sup>The Biodesign Center for Molecular Design and Biomimetics, Arizona State University, Tempe AZ, United States

\*Correspondence should be addressed to <u>martin.schnermann@nih.gov</u> and <u>jpresche@uci.edu</u> <sup>‡</sup>These authors contributed equally to the work.

# TABLE OF CONTENTS

Figures S1-S20	<b>S2-15</b>
Materials and Methods	S16-22
Rosetta Methods	822-36
Synthetic Procedures	836-41
References	S41-42
NMR Spectra	<b>S43-60</b>



**Figure S1.** 2D NOESY spectrum (diagonal peak suppression) of CouLuc-1-NMe<sub>2</sub> in DMSO- $d_6$  showing the correlation of H<sub>d</sub> and H<sub>e</sub>.





Figure S2. Chromatography-free synthesis of cyanomethylene coumarin 2a from commercial coumarin. Starting from a flame-dried round-bottom flask under nitrogen; (a) The flask was charged with THF, CH<sub>3</sub>CN, and *n*-BuLi at -78 °C; (b) After addition of coumarin 1a in THF; (c) Reaction quenched with aqueous NH<sub>4</sub>Cl solution and the -78 °C bath was removed; (d) Extraction with EtOAc; (e) Addition of 0.5 M HCl and stirred at 1000 rpm; (f) Precipitation of cyanomethylene coumarin 2a as a yellow solid; (g) Vacuum filtration; (h) Isolated cyanomethylene coumarin 2a.



Figure S3. Chromatography-free synthesis of CouLuc-1-NMe<sub>2</sub> from cyanomethylene coumarin. Starting from a flame-dried round-bottom flask under nitrogen; (a) Flask charged with 2a, D-cysteine, NaHCO<sub>3</sub> and degassed EtOH; (b) Reaction after >75% conversion; (c) Crude mixture after removing EtOH; (d) After triturating with EtOAc; (e) Color change after acidifying with 1.0 M HCl; (f) After centrifugation and supernatant removal; (g) Transferred product to round-bottomed flask with MeOH/H<sub>2</sub>O, red color change; (h) Lyophilized CouLuc-1-NMe<sub>2</sub>.



Figure S4. CouLuc-1 analogs are competent, albeit weak, emitters with Fluc. (a) Light emission of CouLuc-1 analogs  $(2.5-250 \ \mu\text{M})$  or D-luc  $(2.5-250 \ \mu\text{M})$  when incubated with ATP (1 mM), coenzyme A (1 mM) and recombinant Fluc (160 nM). Emission intensities are plotted as total photon flux values. Error bars represent the standard error of the mean for n = 3 experiments. (b) Tabulated photon outputs from (a). Relative emission values for each analog (compared to D-luc) at 100  $\mu$ M are also listed



**Figure S5. Biochemical analyses of Fluc with CouLuc-1 analogs**. (a) Kinetics studies revealed CouLuc-1 analogs were poor binders of Fluc. (b) Kinetic constants shown are apparent values, determined via measurements of the initial rates of light emission over a range of substrate concentrations. <sup>[a]</sup>Values were normalized to emission of Fluc/D-luciferin. Error bars represent the standard error of the mean for n = 3 experiments. <sup>[b]</sup>Kinetic parameters could not be determined due to low levels of light production.



Figure S6. Comparison of CouLuc-1 analogs to other synthetic luciferins. (a) Chemical structures of the synthetic luciferins tested. (b) CouLuc-1 analogs or synthetic luciferins (2.5-250 µM) were incubated with ATP (1 mM), coenzyme A (1 mM) and recombinant Fluc (160 nM). Emission intensities are plotted as total photon flux values. Error bars represent the standard error of the mean for n = 3 experiments. (c) Tabulated photon outputs from (b) with [luciferin] = 100 µM. Relative emission values for each analog (compared to D-luciferin) are also listed.

1.6 ± 0.02 x 10<sup>7</sup>

 $2.2 \pm 0.04 \times 10^7$ 

 $3.4 \pm 0.1 \times 10^8$ 

2.7 ± 0.06 x 10<sup>9</sup>

 $2.4 \pm 0.04 \times 10^9$ 

0.018 ± 0.0004

0.27 ± 0.01

 $2.12 \pm 0.05$ 

 $1.92 \pm 0.04$ 

4'-MorphoLuc

7'-MorpipLuc

7'-DMAMeLuc

7'-pyrLuc

Luciferin	BL λ <sub>max</sub> (nm)	FL ۸	FL λ <sub>max</sub> (nm)			
	(with Fluc)	pH 7.4 PBS	MeOH	DMF		
CouLuc-1-NMe <sub>2</sub>	620	627	650	609		
CouLuc-1-NH <sub>2</sub>	597	593	588	476		
CouLuc-1-OH	625	600	541	644		

Table S1. Bioluminescence and fluorescence emission of CouLuc-1 analogs.



**Figure S7. The binding pocket of Fluc does not accommodate the CouLuc-1 architecture.** (a) CouLuc-1-NMe<sub>2</sub> was docked into the Fluc active site (PDB: 4G36) using the RosettaMatch algorithm.<sup>1-2</sup> Residues within 5 Å of the bound luciferin are highlighted in orange. (b-c) Zoom-in view of (a). The coumarin portion of the luciferin is located near residues adjacent to C4' in bound D-luc.



**Figure S8. Searching for a complementary luciferase via Rosetta-guided library design.** (a) Residues within 6 Å of the docked CouLuc-1-NMe<sub>2</sub> scaffold were subjected to RosettaDesign.<sup>1-2</sup> From the analysis, 40 residues were mutated (orange). (b-c) Zoom-in view of (a). Active site residues sculpted to accommodate the CouLuc-1 structures mitigating the steric clash observed in Figure S7b was mitigated. (d). From the analysis, 20 of the 40 residues mutated by Rosetta were targeted for library construction.



Figure S9. Evolving a brighter luciferase for CouLuc-1-NMe<sub>2</sub> via RosettaDesign. (a) Functional mutants identified from on-plate screens were picked and subjected to two secondary screens. In the first round, luciferase expression was auto-induced<sup>3</sup> and mutants with >10-fold light emission (compared to Fluc) were re-examined via IPTG induction. (b) Variants with reproducible improvements were considered hits and sequenced. (c) Unique sequences identified from (b). Plasmids encoding mutant hits were isolated and re-introduced to *E. coli*. The magnitude of improvement was re-analyzed in a final assay using IPTG induction. Relative light emissions are plotted as fold over the native enzyme. Error bars represent the standard error of the mean for n = 3 experiments.



Figure S10. Evolving a brighter luciferase for CouLuc-1-OH via RosettaDesign. (a) Functional mutants identified from on-plate screens were picked and subjected to two secondary screens. In the first round, luciferase expression was autoinduced<sup>3</sup> and mutants with >10-fold light emission (compared to Fluc) were re-examined via IPTG induction. (b) Variants with reproducible improvements were considered hits and sequenced. (c) Unique sequences identified from (b). Plasmids encoding these mutants were isolated and re-introduced to *E. coli*. The magnitude of improvement was re-analyzed in a final assay using IPTG induction. Relative light emissions are plotted as fold over the native enzyme. Error bars represent the standard error of the mean for n = 3 experiments.



Figure S11. Identifying complementary luciferases for CouLuc-1 analogs via semi-rational library design. (a-c) CouLuc-1-NH<sub>2</sub> and (d-e) CouLuc-1-OH were screened against a panel of mutant luciferases using a protocol from Rathbun, *et al.*,<sup>4</sup> with some modifications. Bacteria harboring the luciferase gene were induced for protein expression in a 96 deep-well plate. The cells were pelleted and resuspended in phosphate buffer (250 mM sodium phosphate, pH 8). Each luciferin was added (100  $\mu$ M) and the plate was imaged, and the luminescent values for each mutant were referenced to native Fluc. Mutants with >5-fold improvement in flux (black) with (b) CouLuc-1-NH<sub>2</sub> or (e) CouLuc-1-OH were classified as "hits" and their sequences were listed in (c) and (f), respectively.



Figure S12. Improved light emission was recapitulated with recombinant Pecan (a) Light emission of CouLuc-1 analogs (250–2.5  $\mu$ M) when incubated with ATP (1 mM), coenzyme A (1 mM) and recombinant Pecan (160 nM). Emission intensities are plotted as total photon flux values. Error bars represent the standard error of the mean for n = 3 experiments. (b) Tabulated photon outputs from (a) with [luciferin] = 100  $\mu$ M. Fold improvements for each analog with Pecan (compared to Fluc) are also listed.



Figure S13. Biochemical analyses of Fluc with CouLuc-1 analogs. (a) Kinetics studies revealed CouLuc-1 analogs were poor binders of native luciferase. (b) Kinetic constants are apparent values, determined via measurements of initial light emission over a range of substrate concentrations. <sup>[a]</sup>Values were normalized to emission of Fluc/D-luciferin. Error bars represent the standard error of the mean for n = 3 experiments. <sup>[b]</sup>Kinetic parameters could not be determined due to low photon outputs.



Figure S14. Red-shifted bioluminescence was maintained with Pecan. (a) Recombinant Pecan was incubated with CouLuc-1 analogs and emission spectra were recorded. (b) Emission maxima  $(\lambda_{em})$  for each analog. The corresponding emission maxima with Fluc are also shown.



Figure S15. Cellular imaging with Pecan and CouLuc-1-NMe<sub>2</sub>. HEK293 cells (5 x 10<sup>4</sup>) expressing Fluc or Pecan were incubated with CouLuc-1-NMe<sub>2</sub> (250–2.5  $\mu$ M) or D-luciferin (250–2.5  $\mu$ M). Transfection efficiencies were determined via co-expression of GFP. (a) Maximum photon outputs ([luciferin] = 250  $\mu$ M) were determined by monitoring signals over time. (b) Peak emission intensities for each probe combination are shown as photon flux values per cell. Error bars represent the standard error of the mean for n = 3 experiments. (c) Tabulated photon outputs from (b) with [luciferin] = 250  $\mu$ M. Relative emission values for each luciferase/luciferin pair (compared to Fluc/D-luciferin) are also listed.



Figure S16. Improved light emission observed with Pecan and other CouLuc-1 analogs *in cellulo*. HEK293 cells (5 x 10<sup>4</sup>) expressing Fluc or Pecan were incubated with CouLuc-1-NH<sub>2</sub> (250–2.5  $\mu$ M), CouLuc-1-OH (250–2.5  $\mu$ M) or D-luciferin (250–2.5  $\mu$ M). Transfection efficiencies were determined via co-expression of GFP. (a) Peak emission intensities for each probe combination are shown as photon flux values per cell. Error bars represent the standard error of the mean for n = 3 experiments. (b) Tabulated photon outputs from (a) with [luciferin] = 250  $\mu$ M. Relative emission values for each luciferase/luciferin pair (compared to Fluc/D-luciferin) are also listed.



**Figure S17. Robust light emission observed in DB7 cells**. DB7 cells stably expressing Pecan (5 x  $10^4$ ) were incubated with CouLuc-1 analogs (250–2.5  $\mu$ M). Photon outputs were measured immediately post substrate addition. Emission intensities are plotted as total photon flux values and error bars represent the standard error of the mean for n = 3 experiments.



Figure S18. Cellular light emission from Pecan/CouLuc-1-NMe<sub>2</sub> is comparable to other redemitting bioluminescence probes. HEK293 cells (5 x 10<sup>4</sup>) expressing mutant luciferases or Fluc were incubated with either D-luciferin (250–2.5  $\mu$ M), CouLuc-1-NMe<sub>2</sub> (250–2.5  $\mu$ M), CycLuc1 (250–2.5  $\mu$ M) or AkaLumine (250–2.5  $\mu$ M). (a) Peak emission intensities for each probe combination are shown as photon flux values per cell. Error bars represent the standard error of the mean for n = 3 experiments. (b) Tabulated photon outputs from (a) with [luciferin] = 250  $\mu$ M. Relative emission values for each luciferase/luciferin pair (compared to Fluc/D-luciferin) are also listed.



Figure S19. Pecan/CouLuc-1-NMe<sub>2</sub> produces a significant amount of near infrared photons. Luciferase-expressing DB7 cells (5 x 10<sup>4</sup>) were treated with either CouLuc-1-NMe<sub>2</sub> (100  $\mu$ M), D-luciferin (100  $\mu$ M), CycLuc1 (100  $\mu$ M), AkaLumine (100  $\mu$ M) or furimazine (1:100 dilution from commercial stock). Photons produced in the near-infrared window were recorded by measuring through a Cy5.5 emission filter (695–770 nm). Emission intensities are plotted as total photon flux values and error bars represent the standard error of the mean for n = 3 experiments.



**Figure S20. Multiplexed imaging with Pecan/CouLuc-1-NMe<sub>2</sub>.** Gradients of DB7 cells (1-4 x  $10^4$ ) expressing Pecan, Akaluc, or Antares were plated in a 96-well plate as shown. (a) Raw luminescent images from sequential substrate administration of CouLuc-1-NMe<sub>2</sub> (100  $\mu$ M), AkaLumine (100  $\mu$ M), and furimazine (1:100 dilution from commercial stock). Data are representative of n = 3 replicates. (b) Quantified photon outputs for the images in (a). Photon flux from wells containing a single population of 4.0 x  $10^4$  luciferase-expressing cells were plotted. Minimal crosstalk was observed between Pecan/CouLuc-1-NMe<sub>2</sub> and Akaluc/AkaLumine. Error bars represent the standard error of the mean for n = 3 experiments.

#### **General biological methods**

#### Fluorescent spectra and assays

Absorption curves were obtained on a Shimadzu UV-2550 spectrophotometer operated by UVProbe 2.32 software. Fluorescence traces were recorded on a PTI QuantaMaster steady state spectrofluorometer operated by FelixGX 4.2.2 software, with 5 nm excitation and emission slit widths, 0.1 s integration rate, and enabled emission correction. Data analyses and curve fitting were performed using MS Excel 2019 and GraphPad Prism 8. Luciferins (10  $\mu$ M) were analyzed in a variety of solvents.

#### Bioluminescence emission spectra with recombinant luciferases

Emission spectra for all luciferin analogs were recorded on an Agilent Cary Eclipse Fluorescence Spectrophotometer. Each luciferin (100  $\mu$ M) was incubated in an Eppendorf tube with ATP (1 mM) and diluted to 1 mL with bioluminescence reaction buffer (20 mM Tris•HCl, 0.5 mg/mL BSA, 0.1 mM EDTA, 1 mM TCEP, 2 mM MgSO<sub>4</sub>, pH = 7.8). Purified luciferase enzyme (6–600  $\mu$ g) was added, and an aliquot (700  $\mu$ L) was transferred to a 10 mm pathlength cuvette. The emission slit widths were set to 5–10 nm. The detector gain was set to 600 mV. Emission data were collected at 1 nm intervals from 400–850 nm at ambient temperature. The acquisition times were set to 1–60 s/wavelength depending on the amount of light produced from each sample. Light emission was recorded as relative luminescence units (RLU), and the intensities were normalized. Area under the curve was estimated via the trapezoid rule on MS Excel.

#### Bioluminescence emission spectra with luciferase expressing cells

For *in cellulo* emission spectra, 1 x 10<sup>6</sup> DB7 cells stably expressing the luciferase of interest<sup>5-6</sup> were added to an Eppendorf tube in DMEM with 10% FBS. Cells were then incubated with luciferin (200  $\mu$ M final concentration) diluted in PBS or DMSO (7-NMe2-CouLuc1 only, 10% DMSO final concentration) and an aliquot (700  $\mu$ L) was transferred to a 10 mm pathlength cuvette. The emission slit widths were set to 20 nm. The detector gain was set to 800 mV. Emission data were collected at 5 nm intervals from 400–850 nm at ambient temperature. The acquisition times were set to 1 s/wavelength for all samples. Light emission was recorded at relative luminescence units (RLU) and the intensities were normalized. Area under the curve was estimated via the trapezoid rule on MS Excel.

# Reagents

All reagents purchased from commercial supplies were of analytical grade and used without further purification. 4'-MorphoLuc, 7'-MorpipLuc, 7'-DMAMeLuc and 7'-pyrLuc, CycLuc1 were prepared and used as previously described.<sup>5,7-8</sup>

# General bioluminescence imaging protocol

All analyses were performed in black 96-well plates (Grenier Bio One). Plates containing luminescent reagents were allowed to sit at room temperature for 5 min post-luciferin addition, and were then imaged in a light-proof chamber with an IVIS Lumina II (Xenogen) CCD camera chilled to -90 °C. The stage was kept at 37 °C during the imaging session, and the camera was controlled using Living Image software. The exposure time was 1–60 s, and data binning levels were set to medium. Regions of interests were selected for quantification and total flux values were

analyzed using Living Image software. All data were exported to Microsoft Excel or Prism (GraphPad) for further analyses.

#### General cell culture methods

HEK293 and DB7 cells were cultured in complete media: DMEM (Corning) containing 10% (v/v) fetal bovine serum (FBS, Life Technologies), 4.5 g/L glucose, 2 mM L-glutamine, penicillin (100 U/mL), and streptomycin (100 µg/mL, Gibco). DB7 cells stably expressing Fluc were generated according to Jones et al. via transduction with ecotropic retrovirus (Phoenix packaging system).4-<sup>5</sup> DB7 cells stably expressing Pecan, Akaluc, and Antares were generated according to Rathbun et al. via CRISPR-mediated gene insertion.<sup>6</sup> For transient transfection experiments, HEK293 cells were plated 24-48 h prior to transfection in tissue culture treated 6-well dishes (Corning). Transfections were performed with luc2-IRES-eGFP or Pecan-IRES-eGFP plasmids using Lipofectamine 2000 according to the manufacturer's instructions when cells were 75-80% confluent (1-2 d post plating). Cells were manipulated 24-48 h post transfection. Expression of all transient and stable cell lines were checked via flow cytometry using an ACEA NovoCyte flow cytometer and the appropriate filter settings. Fluorescence was analyzed and quantified using the NovoExpress software (ACEA). Stably expressing luciferase cells were maintained under puromycin selection (20 µg/mL) to ensure gene incorporation was preserved. Cells were incubated at 37 °C in a 5% CO<sub>2</sub> humidified chamber. Cells were serially passaged using trypsin (0.25% in HBSS, Gibco).

# General cloning methods

Polymerase chain reaction (PCR) methods were performed to isolate the luciferase and IRESeGFP genes. Mutant luciferase inserts were amplified from pET vectors using the following primers:

5'- CGACTCACTATAGGGAGACCCAAGCTTATGGAAGATGCCAAAAACATTAAGAAG -3' and 5'-CACCGGCCTTATTCCAAGCGGCTTCGGCCAGTAACGTTTACACGGCGATCTTGCC-3'

IRES-eGFP insert was amplified from pcDNA vectors using the following primers: 5'- AAGGGCGGCAAGATCGCCGTGTAAACGTTACTGGCCGAAGCCGCTTGGAATAAG-3' and 5'-GCCGCCAGTGTGATGGATATCTGCAGAATTCttaCTTGTACAGCTCGTCCATGC-3'

All PCR reactions (unless otherwise stated) were performed in a BioRad C3000 Thermocycler using the following conditions: 1) 95 °C for 3 min, 2) 95 °C for 30 s, 3) Tm of primers for 30 s, 4) 72 °C for 3 min, repeat steps 2-4 twenty times, then 72 °C for 5 min, and hold at 12 °C until retrieved from the thermocycler. Linearized vectors were generated via digestion with restriction enzymes *Hlind*III and *Xho*I (New England BioLabs). The linearized vectors were combined with the appropriate luciferase insert by Gibson assembly (50 °C for 60 min). A portion of the reactions (3.0  $\mu$ L) was directly transformed into TOP10 competent *E. coli* cells. Colonies containing the genes of interest were expanded overnight in 5 mL LB broth supplemented with ampicillin (100  $\mu$ g/mL) or kanamycin (100  $\mu$ g/mL) and DNA was extracted from colonies using a Zymo Research Plasmid Mini-prep Kit. Sequencing analysis confirmed successful plasmid generation.

# In cellulo bioluminescence imaging

Stably expressing luciferase cells, or transiently transfected HEKs were plated in DMEM containing 10% FBS (90  $\mu$ L, 50,000 cells/well). Measurements were carried out in triplicate using black 96-well plates (Grenier Bio One). Luciferin analogs (0–250  $\mu$ M) were prepared as a 10X

stock in PBS and then 10  $\mu$ L was added to assay wells. Images for all assays were acquired as described above.

#### Construction of combinatorial codon mutagenesis (CCM) libraries

DNA inserts for the combinatorial libraries (on average 3–4 mutations per clone) were generated as described by Belsare, *et al.*, with some modifications.<sup>9-10</sup> The library template was first amplified using primers ZY040 and ZY041 (Table S2). The following thermal cycling conditions was used in a BioRad C3000 Thermocycler: 1) 95 °C for 3 min, 2) 95 °C for 30 s, 3) 65 °C for 30 s, 4) 72 °C for 45 s min, repeat steps 2-4 twenty times, then 72 °C for 5 min, and hold at 12 °C until retrieved from the thermocycler.

The forward fragment reactions were performed using an equimolar of mixture of mutagenic forward primers and ZY041 (Table S2). The reverse fragment reactions were performed using an equimolar mixture of mutagenic reverse primers and ZY040 (Table S2). The following thermal cycling conditions were used for the fragmentation reaction: 1) 95 °C for 3 min, 2) 95 °C for 30 s, 3) 60 °C for 30 s, 4) 72 °C for 45 s min, repeat steps 2-4 seven times, then 72 °C for 5 min, and hold at 12 °C until retrieved from the thermocycler. These reactions were used in a joining PCR reaction using the following conditions: ZY040 (1  $\mu$ L, 100  $\mu$ M), ZY041 (1  $\mu$ L, 100  $\mu$ M), 10x Q5® Reaction Buffer (6  $\mu$ L), 10x Q5® GC Enhancer Buffer, 1:4 dilution of the forward fragment reaction (4  $\mu$ L), 1:4 dilution of the reverse fragment reaction (4  $\mu$ L), dNTPs (1  $\mu$ L, 0.8 mM), and Q5® High-Fidelity DNA polymerase (0.3  $\mu$ L, 1U, New England BioLabs) totaling 30  $\mu$ L. DNA was amplified using thermal cycling conditions for insert amplification as descried above. This PCR product was used as template for the second round of fragmentation (12 cycles) and joining PCRs. Mutagenesis was confirmed using Sanger sequencing (Genewiz).

Library DNA inserts were incorporated into linearized pQE vector. The linearized pQE vector was generated via digestion with restriction enzymes *BamH*I and *Xba*I. Library inserts were assembled with the linearized pET vectors using Gibson assembly. For each assembly, 25 ng of the linearized vector was combined with insert (5:1 insert:vector ratio) and added to 5  $\mu$ L of master mix mixed with 5  $\mu$ L NanoPure H<sub>2</sub>O. The mixtures were incubated at 50 °C for 60 min, then the entire reaction mixture was transformed into chemically competent TOP10 E. coli (70  $\mu$ L). Transformants were recovered with SOC (100  $\mu$ L) for 30 mins at 37 °C and 25  $\mu$ L plated per square, agar plate containing ampicillin.

 Table S2: Primers used to construct Rosetta CCM library. The bases highlighted in red denote sites targeted for mutagenesis.

Forward CCM Primers	
ZY040	ATCGCATCACCATCACCGGATCCATGGAAGATGCCAAAAACATTAAGAAGG
RosCCM1-F-218	CGCTTGTGTCndtTTCAGTCATGCCC
RosCCM1-F-221	CGATTCAGTndtGCCCGCG
RosCCM1-F-222	GATTCAGTCATndtCGCGACCCCATC
RosCCM1-F-229	GACCCCATCTTCGGCndtCAGATCATC
RosCCM1-F-245	GCCATTTCACndtGGCTTCGGCAT
RosCCM1-F-246	CCATTTCACCACndtTTCGGCATGTT
RosCCM1-F-247	CACCACGGCndtGGCATGTTC
RosCCM1-F-250	CTTCGGCATGndtACCACGCTG
RosCCM1-F-251	CTTCGGCATGTTCndtACGCTGG
RosCCM1-F-254	TCACCACGCTGndtTACTTGATCTG
RosCCM1-F-314	GATCGCCndtGGCGGG
RosCCM1-F-338	GCATCCGCndtGGCTACGG
RosCCM1-F-342	AGGGCTACGGCndtACAGAAACAA
RosCCM1-F-343	CTACGGCCTGndtGAAACAACTAGTG
RosCCM1-F-347	CTGACAGAAACAACTndtGCCATTCTGATCACC
RosCCM1-F-351	TGCCATTCTGndtACCCCCGAAG
RosCCM1-F-352	CATTCTGATCndtCCCGAAGGGG
RosCCM1-F-420	GGCTGCACndtGGCGACATCGC
RosCCM1-F-437	TCATCGTGGACndtCTGAAGAGCC
RosCCM1-F-519	TGACCGGCndtTTGGACGCC

Reverse CCM Primers	
ZY041	TTTCGTTTTATTTGATGCCTCTAGATTACACGGCGATCTTGCCGCCCTTCTT
RosCCM1-R-218	GGGCATGACTGAAahnGACACAAGCG
RosCCM1-R-221	CGCGGGCahnACTGAATCG
RosCCM1-R-222	GATGGGGTCGCGahnATGACTGAATC
RosCCM1-R-229	GATGATCTGahnGCCGAAGATGGGGTC
RosCCM1-R-245	ATGCCGAAGCCahnGTGAAATGGC
RosCCM1-R-246	AACATGCCGAAahnGTGGTGAAATGG
RosCCM1-R-247	GAACATGCCahnGCCGTGGTG
RosCCM1-R-250	CAGCGTGGTahnCATGCCGAAG
RosCCM1-R-251	CCAGCGTahnGAACATGCCGAAG
RosCCM1-R-254	CAGATCAAGTAahnCAGCGTGGTGA
RosCCM1-R-314	CCCGCCahnGGCGATC
RosCCM1-R-338	CCGTAGCCahnGCGGATGC
RosCCM1-R-342	TTGTTTCTGTahnGCCGTAGCCCT
RosCCM1-R-343	CACTAGTTGTTTCahnCAGGCCGTAG
RosCCM1-R-347	GGTGATCAGAATGGCahnAGTTGTTTCTGTCAG
RosCCM1-R-351	CTTCGGGGGT <mark>ahn</mark> CAGAATGGCA
RosCCM1-R-352	CCCCTTCGGGahnGATCAGAATG
RosCCM1-R-420	GCGATGTCGCCahnGTGCAGCC
RosCCM1-R-437	GGCTCTTCAGahnGTCCACGATGA
RosCCM1-R-519	GGCGTCCAAahnGCCGGTCA

#### Primary screening protocol

The aforementioned agar plates were sprayed with either a solution of CouLuc-1-NMe<sub>2</sub> or CouLuc-1-OH (100–500  $\mu$ M, 500  $\mu$ L per plate). The plates were incubated at 25 °C for 5 minutes and imaged as described above. Light emitting colonies were picked and grown for secondary screenings.

#### Secondary screening protocol

Hits from the primary screen were further analyzed as described in Jones, *et al.*, with some modifications.<sup>5</sup> Light-emitting colonies from the agar plates were picked and expanded in LB broth containing ampicillin (100 µg/mL, LB-AMP) in a 96-well deep-well plate (500 µg/well). The plate was incubated at 37 °C overnight. An aliquot of the overnight culture (4 µL) was then used to inoculate 400 µL of auto-induction LB media, and the cells were incubated as 30 °C with shaking (250 rpm) for 24 h. The remaining starter cultures were mixed with 50% glycerol (1:1) and stored at -80 °C for subsequent plasmid recovery and sequencing analysis. The cells were pelleted by centrifugation (4000 rpm for 10 min) and resuspended in phosphate buffer (600 µL, 250 mM sodium phosphate, pH = 7.8). Bacterial culture (90 µL) was added to 96-well black plates, followed by a 10X solution of luciferin and ATP in phosphate buffer (10 µL, 250 mM phosphate, pH = 7.8, 100 µM luciferin and 1 mM ATP final concentration). The plate was then imaged as described above. Mutants with light emission 10-fold greater than wild type Fluc were considered as hits.

The panel of mutants from above was further validated in a second round of analysis. TOP10 E. coli cells expressing the desired mutants (glycerol stocks) were used to inoculate 5 mL LB-AMP media. The cultures were incubated at 37 °C overnight. An aliquot of the starter culture (150  $\mu$ L) was used to inoculate a fresh solution of LB-AMP (5 mL) and incubated at 37 °C to mid-log phase (O.D.<sub>600</sub> ~0.8). The cultures were then induced with isopropyl β-D-1- thiogalactopyranoside (IPTG, 500  $\mu$ M final concentration), and incubated at 23 °C for 16–18 h. The cells were harvested by centrifugation at 3600 rpm for 15 min. The cells were pelleted by centrifugation (4000 rpm for 10 min) and resuspended in phosphate buffer (600  $\mu$ L, 250 mM sodium phosphate, pH = 7.8). Bacterial culture (90  $\mu$ L) was added to 96-well black plates, followed by a 10X solution of luciferin and ATP final concentration). The plate was then imaged as described above. Mutants with reproducible improvement (>10-fold over Fluc) were sequenced.

#### Complete analog/mutant luciferase screen

The panel of luciferin analogs was screened against a library of functional luciferase mutants described in Rathbun, *et al.*<sup>4</sup> BL21 *E. coli* cells expressing mutant luciferases (glycerol stocks) were used to inoculate LB-Kan media in a 96-well deep-well plate (500  $\mu$ L/well). The plate was incubated at 37 °C overnight. An aliquot of the overnight culture (4  $\mu$ L) was used to inoculate 400  $\mu$ L of auto-induction LB media<sup>3</sup>, and the cells were incubated at 30 °C with shaking (250 rpm) for 24 h. The cells were pelleted by centrifugation at 4000 rpm for 10 min and resuspended in sodium phosphate buffer (600  $\mu$ L, 100 mM, pH 8). Cell lysate was spread across six cells (90  $\mu$ L/well) on six different 96-well black plates. Native Fluc expressing bacteria were included in each screen as a control for compound integrity. To each well, a 10X solution of luciferin and ATP in phosphate buffer (10  $\mu$ L, 250 mM phosphate, pH = 7.8, 250  $\mu$ M luciferin and 1 mM ATP final concentration)

was added, and the plate was imaged as described above. This process was repeated until all compounds were imaged with all 222 luciferase mutants.

#### Substrate unmixing analysis with orthogonal pairs

Substrate unmixing was conducted using ImageJ (installed under the FIJI package) as described in Rathbun, *et al.*<sup>6</sup> Luminescence images containing raw photon counts were imported into FIJI and subjected to a 2-pixel median filter. Next, the signal at each pixel was min-max scaled to lie between 0 and 65535 (the maximum value that can be stored in a 16-bit image). Images were then stacked, and an additional image containing the maximum value of the stack was computed (as a Z projection). This new image was added to the stack, and signal was unmixed using the ImageJ plugin developed by Gammon *et al.*<sup>11</sup> Pseudocolors were assigned in FIJI through the "Merge Channels" tool.

#### **Recombinant protein expression and purification**

Luciferases were expressed and purified as described by Jones, et al.<sup>5</sup> The pET-luciferase plasmids (WT, Pecan) were transformed into chemically competent BL21 E. coli cells. The transformants were plated on agar plates containing kanamycin. Cells were expanded in LB-Kan at 37 °C overnight. The overnight culture (20 mL) was used to inoculate 1 L LB-Kan and incubated at 37 °C to mid-log phase (O.D.~0.8). The culture was then induced with isopropyl  $\beta$ -D-1thiogalactopyranoside (IPTG, 500 µM final concentration), and incubated at 22 °C for 16–18 h. The cells were harvested at 4 °C by centrifugation at 4000 rpm for 15 min. Cell pellets were resuspended in 40 mL of phosphate buffer (50 mM phosphate, 300 mM NaCl, 1 mM dithiothreitol (DTT), and 1 mM phenylmethylsulfonyl fluoride, pH = 7.4). Lysozyme (2 mg) was added, and the cells were sonicated and centrifuged at 10000 rpm for 1 h at 4 °C. WT Fluc and mutant luciferases were purified from clarified supernatants using nickel affinity chromatography (BioLogic Duo Flow Chromatography System, Bio-Rad). Proteins were dialyzed into a Tris-acetate buffer (25 mM Tris-acetate, 1 mM EDTA, and 0.2 mM ammonium sulfate, pH = 7.8) at 4 °C for 16 h. DTT (1 mM final concentration) and 15% glycerol were added to the dialyzed samples prior to storage at -20°C. Final protein concentrations were determined using absorbance at 280 nm using a JASCO V730 UV-vis spectrophotometer. SDS-PAGE was also performed to verify protein purify, and gels were stained with Coomassie R-250.

# Light emission assays with recombinant luciferase

Bioluminescence assays were performed as described by Jones, *et al.*<sup>5</sup> Measurements were carried out in triplicate, using solid black, flat-bottom, 96-well plates (Grenier Bio One). Assay wells contained purified Fluc (0 or 1 mg), luciferin analogs (0–250  $\mu$ M), ATP (Sigma Aldrich, 1 mM), coenzyme-A (trilithium salt, NanoLight Technologies, 1 mM), and diluted with bioluminescence reaction buffer to a total volume of 100  $\mu$ L. Luciferins and ATP were premixed in the wells prior to Fluc addition. Images for all assays were acquired as described above.

#### **Bioluminescence kinetic measurements**

Bioluminescence kinetics assays were performed as described by Jones, *et al.* with some modifications.<sup>5</sup> Measurements were acquired on a Tecan F200 Pro injection port luminometer with a neutral density filter. Reactions were performed in black 96-well flat- bottom plates (Greiner). Solutions of luciferin analog in bioluminescence reaction buffer were prepared (0.2–100  $\mu$ M analog), and 50  $\mu$ L were added to each well. The luminescence from each well was measured for

1.5 s prior to the addition of Fluc or mutant in bioluminescence buffer with ATP. For wells containing D-luciferin, a 1.6  $\mu$ M solution of enzymes (50  $\mu$ L) was used. For other compounds, a 160  $\mu$ M solution of enzyme (50  $\mu$ L) was administered. Following the addition of enzyme, luminescence was recorded every 0.2 s over a 60 s period. Samples were analyzed in triplicate. The peak intensities were determined by averaging the five maximum photon outputs per run.  $K_{\rm M}$  and relative  $k_{\rm cat}$  values were determined using nonlinear regression analyses in Prism (GraphPad).

#### General Rosetta methods

All calculations were carried out using Rosetta master version 60589 SHA1 code: 8442bff4fb7bf2ccb44655e8d15276c9bccfbbd0 using the ref15 score function.<sup>12</sup>

#### Preparing the scaffolds

A high-resolution (2.62 Å) structure of *Photinus pyralis* luciferase (PDB ID: 4G36) was processed to remove water molecules, non-proteinogenic molecules and a second copy of the protein in the asymmetric unit. Mutations present in the Pecan and Akaluc scaffold were made using the prepared 4g36 scaffold. The structures were subjected to an energy minimization using the Rosetta relax protocol to prepare them for subsequent protocols<sup>13</sup> with the following command line:

```
<Path to>/Rosetta/main/source/bin/relax.default.linuxgccrelease -s <input file> @<Path to>/relax.flags
```

The contents of relax.flags was:

```
-nstruct 1
-relax:default_repeats 5
-relax:constrain_relax_to_start_coords
-relax:coord_constrain_sidechains
-relax:ramp_constraints false
-ex1
-ex2
-use_input_sc
-flip_HNQ
-ignore_unrecognized_res
-relax:coord_cst_stdev_0.5
```

#### Preparing the CouLuc-1 ligands

The CouLuc-1 ligands were built in Avogadro: an open-source molecular builder and visualization tool. Version 1.2.0. <u>http://avogadro.cc/<sup>14</sup></u> and subjected to an energy minimization using the UFF force field.<sup>15</sup> The .mol2 files were converted to .params files for use in Rosetta using an internal script. The params files used in the RosettaMatch algorithm are as follows:

The CouLuc-1- NMe<sub>2</sub> params file where LCC stands for CouLuc-1-NMe<sub>2</sub> is as follows:

NAME LCC IO\_STRING LCC Z TYPE LIGAND AA UNK ATOM N7 Ntrp X -0.50 ATOM S2 S X -0.05 ATOM 01 OOC X -0.65 ATOM 02 OOC X -0.65 ATOM 03 OH X -0.55 ATOM C5 CH2 X -0.07

ATOM	С6	CH1	Х	0.02
АТОМ	04	OH	Х	-0.55
Δ.Π.Ο.Μ	C 9	CH1	v	0 02
	NT 4	Nesse	25	0.02
ATOM	N4	Npro	Α	-0.20
A'I'OM	CII	aroC	Х	-0.01
ATOM	NЗ	Nhis	Х	-0.42
ATOM	C10	aroC	Х	-0.01
АТОМ	N2	Nhis	х	-0 42
λπΟM	C13	aroC	v	_0 01
	NC	ALUC		0.01
ATOM	N6	NHZO	Х	-0.36
ATOM	H6	Hpol	Х	0.54
ATOM	H7	Hpol	Х	0.54
ATOM	C12	aroC	Х	-0.01
	N5	N± rp	v	_0 50
	014	NCLP	N	0.00
ATOM	C14	aroc	A	-0.01
ATOM	H15	Haro	Х	0.22
ATOM	H2	Hpol	Х	0.54
ATOM	H14	Haro	Х	0.22
ATOM	C8	CH1	х	0 02
	06	0111 011	v	_0 55
ATOM	00	Оп	A 	-0.55
A'I'OM	Н8	Нро⊥	Х	0.54
ATOM	С7	CH1	Х	0.02
ATOM	05	OH	Х	-0.55
АТОМ	HЗ	Hpol	Х	0.54
	110	Hana	v	0.01
ATOM	TII O	паро	A 	0.20
ATOM	HIZ	наро	Х	0.20
ATOM	H13	Наро	Х	0.20
ATOM	Н9	Наро	Х	0.20
ATOM	H4	Наро	Х	0.20
ATOM	н5	Hano	X	0 20
	11.J	apo	25	0.20
ATOM	C4	000	X	0./3
ATOM	C3	aroC	Х	-0.01
ATOM	N1	Nhis	Х	-0.42
ATOM	C1	aroC	Х	-0.01
ATOM	C15	CH1	x	0 02
λπΟM	C16	C00	v	0.02
ATOM	010	000	^	0.75
ATOM	08	000	Х	-0.65
ATOM	C18	aroC	Х	-0.01
ATOM	C19	aroC	Х	-0.01
ATOM	C20	aroC	Х	-0.01
λ.ΨΟΜ	C17	aroC	v	_0 01
	U17	Uses	25	0.01
ATOM	HI/	Haro	X	0.22
A'I'OM	C25	CHI	Х	0.02
ATOM	F1	F	Х	-0.14
ATOM	F2	F	Х	-0.14
ATOM	F٦	F	x	-0 14
λπΟM	C24	aroC	v	_0 01
ATOM	~~~~	aroc	~	0.01
ATOM	C23	aroc	Х	-0.01
ATOM	C22	aroC	Х	-0.01
ATOM	C21	aroC	Х	-0.01
ATOM	H20	Haro	Х	0.22
λ.ΨΟΜ	NI8	Mhig	v	_0 /2
	001	ATT2		0.42
ATOM	C26	CH3	Х	-0.16
ATOM	H21	Наро	Х	0.20
ATOM	H22	Наро	Х	0.20
ATOM	Н23	Наро	Х	0.20
Δ.Π.Ο.Μ	C27	СНЗ	x	-0 16
		Uara	v	0.10
ATOM	н∠4	наро	X	0.20
ATOM	H25	Наро	Х	0.20
ATOM	H26	Наро	Х	0.20
ATOM	H19	Haro	Х	0.22
ATOM	н1 Я	Haro	x	0 22
7 T O L I	ц1 С	Uame	v	0 20
ATOM	птр	паро	A	0.20
A'I'OM	SI	S	Х	-0.05
ATOM	C2	aroC	Х	-0.01
ATOM	Н1	Haro	Х	0.22

3 501	07	0,1110		0 4 4
A'I'OM	07	ONH2	Х	-0.44
ATOM	H10	loqH	Х	0.54
		C1	01 E	1
BOND	- IIPE	CI	CID	Ŧ
BOND	TYPE	C1	N1	4
BOND	TYPE	N1	C3	4
DOND-		01	20	-
ROND	TIPE	01	SZ	2
BOND	TYPE	C1	S1	4
BOND	TVDF	91	C2	Δ
		21	~~~	-
BOND	TYPE	C2	C3	4
BOND	TYPE	C2	Н1	1
		NT 2	C10	1
BOND_	-		CIU	4
BOND_	TYPE	N2	C13	4
BOND	TYPE	02	S2	2
		<u> </u>	0.2	1
BOND_	- IIPE	52	03	1
BOND	TYPE	S2	Ν7	1
BOND	TYPE	C3	C4	1
DOND		NI C	Q1 0	-
ROND	TIPE	LN 2	CIU	4
BOND	TYPE	NЗ	C11	4
BOND	TYPE	03	C 5	1
DOND-		00 01	222	1
ROND	TIPE	04	IN /	T
BOND	TYPE	С4	07	2
BOND	TYPE	N4	C9	1
DOND_		14 1	011	4
ROND	TYPE	N4	CII	4
BOND	TYPE	N4	C14	4
		04	C 6	1
BOND_		04	00	1
BOND_	TYPE	04	С9	1
BOND	TYPE	C5	C6	1
		C5	ц <i>Л</i>	1
BOND_	-	05	пч	1
BOND_	TYPE	C5	Н5	1
BOND	TYPE	N5	C12	4
		NE	C1 /	4
BOND_		N J	C14	4
BOND_	TYPE	N5	H2	1
BOND	TYPE	05	С7	1
		05	ц <b>2</b>	1
BOND_	- IIPE	05	пэ	1
BOND	TYPE	C6	C7	1
BOND	TYPE	C6	Н9	1
		NG	012	1
BOND_	- IIPE	10 0	CID	T
BOND	TYPE	N6	НG	1
BOND	TYPE	N6	H7	1
		06	0	1
BOND_	- IIPE	06	Co	T
BOND	TYPE	06	Н8	1
BOND	TYPE	C.7	C.8	1
		07	1111	1
BOND_	- IIPE	C7	піі	1
BOND	TYPE	N7	H10	1
BOND	TYPE	C.8	C.9	1
DOND		<u> </u>	1110	1
ROND	TIPE	0	HIZ	Ţ
BOND	TYPE	N8	C26	1
BOND	TYPE	N8	C27	1
		00	C10	4
BOND_	-	00	CIO	4
BOND	TYPE	С9	H13	1
BOND	TYPE	C10	н14	1
DOND-		011	a1 0	1
ROND	TIPE	CII	CIZ	4
BOND	TYPE	C12	C13	4
BOND	TYPE	C14	H15	1
DOND		011	010	1
ROND	TIPE	CIS	CT0	T
BOND	TYPE	C15	H16	1
BOND_	TYPF	08	C16	4
DOM_		010	C1 7	1
ROND	TTTE	CT0	CT/	4
BOND	TYPE	C17	C20	4
BOND_	TYPF	C17	н17	1
DON -		010		<u>_</u>
ROND	T. T. F. F.	CT8	CT3	4
BOND	TYPE	C18	C21	4
BOND_	TYPF	C19	C20	4
- - - - -		010	020	1
ROND	- Л. Х. Ъ. Ę.	CT3	CZ4	4
BOND	TYPE	C20	C25	1
BOND_	TYPF	C21	C22	4
		UL 1	~~~	-

BOND_TYPEC21BOND_TYPEN8BOND_TYPEC22BOND_TYPEC23BOND_TYPEC23BOND_TYPEC24BOND_TYPEC25BOND_TYPEC25BOND_TYPEC25BOND_TYPEC26BOND_TYPEC26BOND_TYPEC26BOND_TYPEC27BOND_TYPEC27BOND_TYPEC27BOND_TYPEC27BOND_TYPEC27BOND_TYPEC27BOND_TYPEC27CHIC8C7PROTON_CHIPROTON_CHI1	H20 1 C22 1 C23 4 C24 4 H19 1 H18 1 F1 1 F2 1 F3 1 H21 1 H22 1	50 55 60	65 70 75 -45	-50 -55 -60 -65	-70 -75 165 170
175 180 185 190 1	195 EXTRA	0			
CHI 2 C9 C8	06 H8	50 55 60	65 70 75 -45	-50 -55 -60 -65	-70 -75 165 170
175 180 185 190 1	195 EXTRA	0	05 70 75 -45	-50 -55 -60 -65	-/0 -/3 105 1/0
CHI 3 N1 C1	C15 C16	•			
CHI 4 N7 S2	O3 C5				
CHI 5 C4 N7	S2 01				
CHI 6 N/ C4 CHI 7 S2 O3	C3 NI				
CHI 8 S2 N7	C4 C3				
CHI 9 O4 C9	N4 C11				
CHI 10 03 C5	C6 04				
CHI 11 CI CIS CHI 12 C19 C20	C16 08 C25 F1				
CHI 13 C23 C22	N8 C26				
NBR_ATOM N7					
NBR_RADIUS 16.480	)287		0 00000	0 00000 177	20 01
ICOOR_INTERNAL	N/ U S2 0	.000000 1	0.000000	0.000000 N/ 1.650062 N7	S2 01 S2 01
ICOOR INTERNAL	01 0	.000000	72.104658	1.437728 S2	N7 01
ICOOR_INTERNAL	02 -110	.996100	68.074449	1.445125 S2	N7 01
ICOOR_INTERNAL	03 -129	.794407	67.944568	1.509427 S2	N7 02
ICOOR_INTERNAL	C6 157	.020210	70.710750	1.410874 03 1.511242 C5	03 S2
ICOOR INTERNAL	04 77	.282034	69.984387	1.402847 C6	C5 O3
ICOOR_INTERNAL	C9 125	.140105	74.095561	1.413122 04	C6 C5
ICOOR_INTERNAL	N4 -109	.511147	70.744428	1.445332 C9	04 C6
ICOOR_INTERNAL	N3 -0	.220766	24.143952 46 184845	1.365802 N4 1.342623 C11	C9 04 N4 C9
ICOOR INTERNAL	C10 -179	.435301	59.581414	1.325031 N3	C11 N4
ICOOR_INTERNAL	N2 -0	.833691	57.581285	1.332176 C10	N3 C11
ICOOR_INTERNAL	C13 0	.541646	58.153548	1.342096 N2	C10 N3
ICOOR_INTERNAL	N6 -1/9	.885440	60.50691/ 50 077458	1.449335 CI3	NZ CIU C13 N2
ICOOR INTERNAL	H7 179	.945780	60.016656	0.985154 N6	C13 H6
ICOOR INTERNAL	C12 179	.862428	62.184716	1.420651 C13	N2 N6
ICOOR INTERNAL	N5 -179	.949517	44.621863	1.328601 C12	C13 N2
LCOOR_INTERNAL	C14 179	.677558	/0.203038	L.324715 N5	C12 C13 N5 C12
ICOOR INTERNAL	H2 -179	.970617	54.849045	0.984976 N5	C12 C14
ICOOR_INTERNAL	H14 179	.967987	61.153361	1.031699 C10	N3 N2
ICOOR_INTERNAL	C8 125	.386647	71.678423	1.475682 C9	04 N4
LCOOR_INTERNAL	06 90	.159142	/1.814346	1.374530 C8	C9 C9
ICOOR INTERNAL	C7 -120	.342.024	77.546124	1.466197 C8	C9 06
ICOOR_INTERNAL	05 150	.569759	65.740398	1.379514 C7	C8 C9
ICOOR_INTERNAL	H3 179	.991726	70.530485	0.970413 05	C7 C8
ICOOR_INTERNAL	H11 117	.079816	69.012841	1.070864 C7	C8 O5
TCOOK TINTERNAL	пız <b>-</b> 121	• 1 / 4 0 / /	03.121032	1.009/12 00	09 01

ICOOR	INTERNAL	H13	117.670342	67.676021	1.069572	С9	04	С8
ICOOR	INTERNAL	Н9	-119.425559	70.515230	1.070763	C6	C5	04
ICOOR	INTERNAL	H4	-120.035866	70.426804	1.069592	C5	03	C6
ICOOR	INTERNAL	Н5	-119.906355	70.417410	1.069976	C5	03	H4
ICOOR	INTERNAL	C4	-83.793754	58.281421	1.467467	N7	S2	01
ICOOR	INTERNAL	C3	178.602413	63.790977	1.496597	C4	N7	S2
ICOOR	INTERNAL	N1	171.710317	59.685217	1.308129	C3	C4	N7
ICOOR	INTERNAL	C1	179.403075	66.538537	1.363242	N1	C3	C4
ICOOR	INTERNAL	C15	178.038432	54.751568	1.475845	C1	N1	C3
ICOOR	INTERNAL	C16	-179.973359	56.742589	1.347238	C15	C1	N1
ICOOR	INTERNAL	08	1.725866	59.229554	1.354592	C16	C15	C1
ICOOR	INTERNAL	C18	179.858798	56.623479	1.354364	08	C16	C15
ICOOR	INTERNAL	C19	0.887588	59.212928	1.412822	C18	08	C16
ICOOR	INTERNAL	C20	-0.844484	61.931272	1.515819	C19	C18	08
ICOOR	INTERNAL	C17	0.091368	61.915940	1.352930	C20	C19	C18
ICOOR	INTERNAL	H17	-179.883717	59.714914	1.087586	C17	C20	C19
ICOOR	INTERNAL	C25	-179.669554	53.469135	1.526954	C20	C19	C17
ICOOR	INTERNAL	F1	-0.147422	65.088860	1.374607	C25	C20	C19
ICOOR	INTERNAL	F2	-120.743410	70.959525	1.384707	C25	C20	F1
ICOOR	INTERNAL	FЗ	-118.465114	70.887590	1.383661	C25	C20	F2
ICOOR	INTERNAL	C24	-179.813659	62.667377	1.407529	C19	C18	C20
ICOOR	INTERNAL	C23	0.444229	58.666119	1.396868	C24	C19	C18
ICOOR	INTERNAL	C22	0.207422	58.151002	1.413573	C23	C24	C19
ICOOR	INTERNAL	C21	-0.508039	63.430140	1.413587	C22	C23	C24
ICOOR	INTERNAL	H20	179.170241	57.531909	1.075128	C21	C22	C23
ICOOR	INTERNAL	N8	-179.834487	58.360800	1.454020	C22	C23	C21
ICOOR_	INTERNAL	C26	-15.367154	57.151155	1.459721	N8	C22	C23
ICOOR_	INTERNAL	H21	-4.544141	65.075936	1.099691	C26	N8	C22
ICOOR	INTERNAL	H22	-118.257943	70.626381	1.111531	C26	N8	H21
ICOOR	INTERNAL	H23	-119.101486	70.203809	1.111081	C26	N8	H22
ICOOR_	INTERNAL	C27	-179.704739	56.873654	1.458277	N8	C22	C26
ICOOR_	INTERNAL	H24	-3.336325	65.036189	1.098860	C27	N8	C22
ICOOR_	INTERNAL	H25	-118.846485	70.514855	1.110651	C27	N8	H24
ICOOR_	INTERNAL	H26	-119.305614	70.093290	1.110606	C27	N8	H25
ICOOR_	INTERNAL	H19	-179.115566	64.471844	1.076073	C23	C24	C22
ICOOR_	INTERNAL	H18	-179.865470	56.842756	1.072154	C24	C19	C23
ICOOR_	INTERNAL	H16	-179.288691	62.704338	1.086883	C15	C1	C16
ICOOR_	INTERNAL	S1	-178.645915	71.214035	1.654766	C1	N1	C15
ICOOR_	INTERNAL	C2	0.064084	84.137315	1.751848	S1	C1	N1
ICOOR_	INTERNAL	Н1	-179.571667	51.154423	1.031194	C2	S1	C1
ICOOR_	INTERNAL	07	179.926420	56.571828	1.227619	C4	N7	C3
ICOOR	INTERNAL	H10	179.925774	60.889832	0.984604	N7	S2	C4

The contents of the CouLuc-1-NH $_2$  ligand params file where LCD stands for CouLuc-1-NH $_2$  are as follows:

NAME	LCD			
IO SI	RING	LCD Z		
TYPE	LIGAN	JD		
AA UN	IK			
ATOM	N7	Ntrp	Х	-0.51
ATOM	S2	S	Х	-0.06
ATOM	01	OOC	Х	-0.66
ATOM	02	OOC	Х	-0.66
ATOM	03	OH	Х	-0.56
ATOM	С5	CH2	Х	-0.08
ATOM	C6	CH1	Х	0.01
ATOM	04	OH	Х	-0.56
ATOM	С9	CH1	Х	0.01
ATOM	N4	Npro	Х	-0.27
ATOM	C11	aroC	Х	-0.01
ATOM	NЗ	Nhis	Х	-0.43
ATOM	C10	aroC	Х	-0.01
ATOM	N2	Nhis	Х	-0.43
ATOM	C13	aroC	Х	-0.01

ATOM	N6	NH2O	Х	-0.37
ATOM	НG	Hpol	Х	0.53
ATOM	H7	Hpol	Х	0.53
ATOM	C12	aroC	Х	-0.01
ATOM	N5	Ntrp	Х	-0.51
ATOM	C14	aroC	Х	-0.01
ATOM	H15	Haro	x	0 22
	1110 1120	Upol	v	0.22
	11Z 111	lipor	A V	0.00
ATOM	п14 С0	CU1	A V	0.22
ATOM	60	CHI	A	0.01
ATOM	06	ОН	X	-0.56
ATOM	H8	Hpol	Х	0.53
ATOM	С7	CH1	Х	0.01
ATOM	05	OH	Х	-0.56
ATOM	HЗ	Hpol	Х	0.53
ATOM	H11	Наро	Х	0.20
ATOM	H12	Hapo	Х	0.20
ATOM	H13	Hapo	Х	0.20
ATOM	H9	Наро	Х	0.20
ATOM	н4	Hapo	X	0 20
ATOM	н5 111	Наро	v	0.20
ATOM	C1	coo	N V	0.20
ATOM	C4 22	000	A 17	0.72
ATOM	C3	aroc	X	-0.01
ATOM	NI	NNIS	X	-0.43
ATOM	C1	aroC	Х	-0.01
ATOM	C15	CH1	Х	0.01
ATOM	C16	C00	Х	0.72
ATOM	08	OOC	Х	-0.66
ATOM	C18	aroC	Х	-0.01
ATOM	C19	aroC	Х	-0.01
ATOM	C20	aroC	Х	-0.01
ATOM	C17	aroC	Х	-0.01
ATOM	H17	Haro	Х	0.22
ATOM	C2.5	CH1	Х	0.01
ATOM	F1	F	X	-0 15
	F2	т Т	X	-0 15
	E3	т Г	v	-0 15
	E 3 4	r a ma C	A V	0.13
ATOM	C24 C22	aroc	A V	-0.01
ATOM	C23	aroc	A	-0.01
ATOM	CZZ	aroc	X	-0.01
ATOM	C21	aroC	Х	-0.01
ATOM	H20	Haro	Х	0.22
ATOM	N8	NH2O	Х	-0.37
ATOM	H21	Hpol	Х	0.53
ATOM	H22	Hpol	Х	0.53
ATOM	H19	Haro	Х	0.22
ATOM	H18	Haro	Х	0.22
ATOM	H16	Наро	Х	0.20
ATOM	S1	s	Х	-0.06
атом	C2	aroC	Х	-0.01
ATOM	н1	Haro	x	0 22
	07	ONH2	v	-0 45
ATOM	U10	Uncl	N V	0.40
DOND		прот		1
BOND_	TIPE		CID N1	1
BOND	TYPE	CI	NI	4
BOND	TYPE-	NI	C3	4
BOND_	TYPE	01	S2	2
BOND_	TYPE	C1	S1	4
BOND	TYPE	S1	C2	4
BOND	TYPE	C2	C3	4
BOND	TYPE	C2	H1	1
BOND	TYPE	N2	C10	4
BOND	TYPE	N2	C13	4
BOND	TYPE	02	s2	2
BOND	TYPE	S2	03	1
BOND	TYPE	S2	N7	1

BOND TVDE	C 3	C1	1														
DOND TIPE	NT2	C10	1														
BOND_TYPE	N 3	CIU	4														
BOND_TYPE	N3	CII	4														
BOND_TYPE	03	C5	1														
BOND_TYPE	C4	Ν7	1														
BOND TYPE	C4	07	2														
BOND TYPE	N4	С9	1														
BOND TYPE	N4	C11	4														
BOND TYPE	N4	C14	4														
BOND TYPE	04	C6	1														
DOND TITE	01	C0	1														
BOND_TIFE	04	09	1														
BOND_TYPE	05	6	1														
BOND_TYPE	05	H4	1														
BOND_TYPE	C5	Н5	1														
BOND_TYPE	N5	C12	4														
BOND_TYPE	N5	C14	4														
BOND_TYPE	N5	Н2	1														
BOND TYPE	05	С7	1														
BOND TYPE	05	ΗЗ	1														
BOND TYPE	C6	C7	1														
BOND TYPE	C.6	Н9	1														
BOND TYPE	N6	C13	1														
BOND TYPE	N6	U6	1														
BOND TYPE	NG	110 117	1														
BOND_TIPE	NO	п/	1														
BOND_TYPE	06	08	1														
BOND_TYPE	06	Н8	1														
BOND_TYPE	C7	C8	1														
BOND_TYPE	С7	H11	1														
BOND_TYPE	N7	H10	1														
BOND TYPE	C8	С9	1														
BOND TYPE	C8	H12	1														
BOND TYPE	N8	H21	1														
BOND TYPE	N8	Н22	1														
BOND TYPE	08	C18	4														
BOND TYPE	C9	U13	1														
BOND TYPE	C10	пт.Э u1./	1														
BOND TIFE	C10 C11	п14 с12	1														
BOND_TYPE	CII alo	CIZ	4														
BOND_TYPE	CIZ	CI3	4														
BOND_TYPE	C14	H15	1														
BOND_TYPE	C15	C16	1														
BOND_TYPE	C15	H16	1														
BOND TYPE	08	C16	4														
BOND TYPE	C16	C17	4														
BOND TYPE	C17	C20	4														
BOND TYPE	C17	H17	1														
BOND TYPE	C18	C19	4														
BOND TYPE	C18	C21	4														
BOND TYPE	C19	C20	4														
BOND TYPE	C19	C24	1														
DOND TIPE	C19	C24 C25	1														
BOND_TIPE	C20	C25	1														
BOND_TYPE	CZI	CZZ	4														
BOND_TYPE	C21	H20	1														
BOND_TYPE	N8	C22	1														
BOND_TYPE	C22	C23	4														
BOND_TYPE	C23	C24	4														
BOND_TYPE	C23	H19	1														
BOND TYPE	C24	H18	1														
BOND TYPE	C25	F1	1														
BOND TYPE	C25	F2	1														
BOND TYPE	C25	F3	1														
CHI 1 C8	C.7	05	H3														
PROTON CHT	1 921	/PT.FC	21 45 50	55	60	65	70	75	-45	-50	-55	-60	-65	-70	-75	165	170
175 120 105	- 3AN	تىتىتى 105		55	00	55	, 0	,	чJ	50	55	00	00	10	, ,	± 0 J	110
TIO TON TOS	, エジU ク マネト	עכי ים וסו	2 21 15 50	55	60	65	70	75	_15	_50	_55	-60	-65	_70	_75	165	170
175 100 100	2 DAN	чг ⊔ Ľ Č 1 ∩ г	D ZI 4J JU	JJ	00	00	10	15	-40	-50	- ) )	-00	-00	- / U	-15	TOJ	110
1/5 180 185	) 190	192	LATKA U														
CHI 3 NI	CL	CIP	) (CIP														

CHI 4 N7	S2	03	C5					
CHI 5 C4	N /	52 C3	OL N1					
CHI 7 S2	03	C5	C 6					
CHI 8 S2	N7	C4	C3					
CHI 9 04	C9	N4	C11					
CHI 10 03	C5	С6	04					
CHI 11 C1	C15	C16	08					
CHI 12 C19	C20	C25	F1					
NBR_ATOM N	17							
NBR_RADIUS	15.401	802	0 000000	0 00000	0 000000	27	<b>a</b> 0	01
ICOOR INTER	NAL NAT.	N / S 2	0.000000		1 649480	N 7	52 52	01
ICOOR INTER	NAL.	01	0.000000	72 115214	1 437728	S2	N7	01
ICOOR INTER	NAL	02	-110.979907	68.095120	1.445125	S2 S2	N7	01
ICOOR INTER	NAL	03	-129.796485	67.884564	1.508898	s2	N7	02
ICOOR_INTER	NAL	C5	47.972804	59.847207	1.411561	03	S2	N7
ICOOR_INTEF	NAL	С6	157.660576	70.738957	1.511080	C5	03	S2
ICOOR_INTEF	NAL	04	77.333973	70.005558	1.402847	C6	C5	03
ICOOR_INTEF	NAL	C9	125.086234	74.080093	1.413900	04	C6	C5
ICOOR_INTER	NAL NAT	N4 C11	-109.502643 -150.220052	7U.72U185 54 143052	1 365902	C9 MA	04 C9	04
ICOOR INTER	NAL NAL	N3	-130.229032	46 223588	1 342216	C11	N4	C9
ICOOR INTER	NAL	C10	-179.432403	59.624923	1.326020	N3	C11	N4
ICOOR INTER	NAL	N2	-0.848435	57.610071	1.331554	C10	N3	C11
ICOOR INTER	NAL	C13	0.552053	58.120141	1.342096	N2	C10	NЗ
ICOOR_INTEF	RNAL	NG	-179.890730	60.506917	1.449335	C13	N2	C10
ICOOR_INTEF	RNAL	НG	-0.115371	59.977458	0.984393	NG	C13	N2
ICOOR_INTEF	NAL	H7	179.952772	59.961946	0.984831	N6	C13	H6
ICOOR_INTER	NAL	CI2	179.862428	62.184/16	1.420651	CI3 C12	NZ C12	N6
ICOOR INTER	NAL NAT.	N5 C14	-1/9.94951/	44.621863	1 324715	N5	C12	NZ C13
ICOOR INTER	NAL.	H15	-179.517871	55.041066	1.032119	C14	N.5	C12
ICOOR INTER	NAL	H2	-179.976464	54.922095	0.984330	N5	C12	C14
ICOOR INTER	NAL	H14	-179.959018	61.152494	1.031712	C10	NЗ	N2
ICOOR_INTEF	RNAL	C8	125.404314	71.733653	1.475916	С9	04	N4
ICOOR_INTEF	RNAL	06	90.149730	71.799851	1.374530	C8	C9	04
ICOOR_INTEF	NAL	H8	179.999645	70.557415	0.969220	06	C8	C9
ICOOR_INTER	NAL	C /	-120.391196	11.52/3/6	1.4655/5	C8	C9	06
ICOOR_INTER	NAL	U2 U3	170.30/803	03.743230 70 545702	1.380198	05	C8	C9 C8
ICOOR INTER	NAL.	н11 н11	117.168004	68.989317	1.070413	C7	C.8	0.5
ICOOR INTER	NAL	H12	-121.158644	63.838599	1.069836	C8	C9	C7
ICOOR INTER	NAL	H13	117.674596	67.713631	1.070064	С9	04	C8
ICOOR_INTEF	RNAL	Н9	-119.374097	70.454273	1.069969	C6	С5	04
ICOOR_INTER	NAL	H4	-119.990464	70.450854	1.069592	C5	03	C6
ICOOR_INTEF	NAL	H5	-119.938832	70.434132	1.070190	C5	03	H4
ICOOR_INTER	NAL	C4 C3	-83.828030	58.301695	1.468382	N/	SZ N7	01
ICOOR INTER	NAL NAL	N1	171 714611	59 715820	1 309092	C4 C3	C4	32 N7
ICOOR INTER	NAL	C1	179.404452	66.574660	1.362844	N1	C3	C4
ICOOR INTER	NAL	C15	179.343162	54.627824	1.477523	C1	N1	C3
ICOOR INTER	NAL	C16	179.978262	56.646772	1.345610	C15	C1	N1
ICOOR_INTEF	NAL	08	0.981830	59.223614	1.354162	C16	C15	C1
ICOOR_INTER	RNAL	C18	179.745138	56.639084	1.351881	08	C16	C15
ICOUR_INTER	NAL	C19	0.484766	59.068241	1.419987	C18	08	C16
TCOOR INTER	NAL	C20	-U.358169 0 167037	61 005151	1,315U/4 1,351577	C19 C19	CI8 C19	U8 C19
ICOOR INTER	NAL	ст/ H17	-179 921795	59 732081	1 088256	$C_{20}$	C20	C19
ICOOR INTER	NAL	C25	-179.891720	53.582674	1.526174	C20	C19	C17
ICOOR INTER	NAL	F1	-0.070420	65.114755	1.374596	C25	C20	C19
ICOOR_INTEF	NAL	F2	-120.759332	70.951926	1.385320	C25	C20	F1
ICOOR_INTER	NAL	F3	-118.384368	70.903342	1.383675	C25	C20	F2
ICOOR_INTER	NAL	C24	-179.946722	62.419046	1.414589	C19	C18	C20
ICOOR_INTER	NAL	C23	0.010362	59.023358	1.398205	C24	C19	C18
TCOOK_INLER	NAL	C22	0.193614	JY.JY2855	1.396//2	C23	CZ4	CTA

TOOOD THEFT	001	0 000007	CO C27C07	1 205542	ann	a	004
ICOOR_INTERNAL	CZI	-0.022927	60.63/68/	1.395543	CZZ	CZ3	CZ4
ICOOR INTERNAL	H20	179.999029	60.022004	1.082887	C21	C22	C23
ICOOR INTERNAL	N8	-179.722109	59.603023	1.416893	C22	C23	C21
ICOOR INTERNAL	H21	179.543056	59.258297	1.030065	N8	C22	C23
ICOOR INTERNAL	H22	-179.490041	59.252862	1.031163	N8	C22	H21
ICOOR INTERNAL	H19	-179.986643	60.635697	1.083038	C23	C24	C22
ICOOR INTERNAL	H18	-179.867044	56.526093	1.071263	C24	C19	C23
ICOOR INTERNAL	H16	-179.940476	62.786240	1.087599	C15	C1	C16
ICOOR INTERNAL	S1	-179.929034	71.177075	1.654766	C1	N1	C15
ICOOR INTERNAL	C2	0.061092	84.158025	1.751119	S1	C1	N1
ICOOR INTERNAL	Н1	-179.547396	51.165815	1.032145	C2	S1	C1
ICOOR INTERNAL	07	179.981870	56.614562	1.227206	C4	N7	CЗ
ICOOR INTERNAL	H10	179.984530	60.814997	0.984262	N7	S2	C4

The contents of the CouLuc-1-OH ligand params file where LCE stands for CouLuc-1-OH are as follows:

NAME	LCE			
IO ST	RING	LCE Z		
TYPE	LIGAN	ND		
AA UN	K			
ATOM	N7	Ntrp	Х	-0.50
ATOM	s2	S	Х	-0.05
ATOM	01	OOC	Х	-0.65
ATOM	02	OOC	Х	-0.65
ATOM	03	OH	Х	-0.55
ATOM	С5	CH2	Х	-0.07
ATOM	С6	CH1	Х	0.02
ATOM	04	OH	Х	-0.55
ATOM	С9	CH1	Х	0.02
ATOM	N4	Npro	Х	-0.26
ATOM	C11	aroC	Х	-0.00
ATOM	NЗ	Nhis	Х	-0.42
ATOM	C10	aroC	Х	-0.00
ATOM	N2	Nhis	Х	-0.42
ATOM	C13	aroC	Х	-0.00
ATOM	N6	NH2O	Х	-0.36
ATOM	НG	Hpol	Х	0.54
ATOM	H7	Hpol	Х	0.54
ATOM	C12	aroC	Х	-0.00
ATOM	N5	Ntrp	Х	-0.50
ATOM	C14	aroC	Х	-0.00
АТОМ	H15	Haro	Х	0.23
ATOM	H2	Hpol	Х	0.54
АТОМ	H14	Haro	Х	0.23
АТОМ	C8	CH1	Х	0.02
АТОМ	06	OH	Х	-0.55
АТОМ	Н8	Hpol	Х	0.54
АТОМ	С7	CH1	Х	0.02
ATOM	05	OH	Х	-0.55
АТОМ	HЗ	Hpol	Х	0.54
АТОМ	H11	Наро	Х	0.21
АТОМ	H12	Наро	Х	0.21
ATOM	Н13	Наро	Х	0.21
АТОМ	Н9	Наро	Х	0.21
АТОМ	H4	Наро	Х	0.21
АТОМ	Н5	Наро	Х	0.21
АТОМ	С4	C00	Х	0.73
АТОМ	C3	aroC	Х	-0.00
ATOM	N1	Nhis	Х	-0.42
ATOM	C1	aroC	Х	-0.00
ATOM	C15	CH1	Х	0.02
ATOM	C16	COO	Х	0.73
ATOM	08	00C	Х	-0.65

ATOM ( ATOM (	C18 C19 C20 C17 H17 C25 F1 F2 F3 C24 C23 C22 C21 H20	aroC aroC aroC Haro CH1 F F F aroC aroC aroC aroC aroC	X X X X X X X X X X X X X X X X X X X	-0.00 -0.00 -0.00 0.23 0.02 -0.14 -0.14 -0.14 -0.00 -0.00 -0.00 0.23
ATOM H ATOM H ATOM H ATOM S ATOM S ATOM G ATOM H ATOM H BOND_TY BOND_TY	H21 H19 H18 H16 S1 C2 H1 C2 H1 C7 H10 YPE YPE	Hpol Haro Haro S aroC Haro ONH2 Hpol C1 C1	X X X X X X X X X X X X X X X X X X X	0.54 0.23 0.23 0.21 -0.05 -0.00 0.23 -0.44 0.54 1
BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY	YPE YPE YPE YPE YPE YPE YPE YPE YPE	N1 O1 C1 S1 C2 C2 N2 N2 N2 O2 S2 S2	C3 S2 S1 C2 C3 H1 C10 C13 S2 O3 N7	4 2 4 4 4 1 4 4 2 1 1
BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY BOND TY	YPE YPE YPE YPE YPE YPE YPE YPE YPE	C3 N3 O3 C4 C4 N4 N4 N4 N4 O4 O4	C4 C10 C11 C5 N7 O7 C9 C11 C14 C6 C9	1 4 4 1 1 2 1 4 4 4 1 1
BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY	YPE YPE YPE YPE YPE YPE YPE YPE YPE	C5 C5 C5 N5 N5 O5 C6 C6	C6 H4 H5 C12 C14 H2 C7 H3 C7 H9 C12	1 1 1 4 4 1 1 1 1 1
BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY BOND_TY	IPE IPE IPE IPE IPE IPE IPE IPE	N6 N6 06 06 C7 C7 N7	H6 H7 C8 H8 C8 H11 H10	1 1 1 1 1 1 1 1

BOND TYPE	C8	C9 1	L								
BOND TYPE	C.8	н12 1									
DOND TYDE	00	C10 /	1								
DOND_TIFE	00	UIO 9	I								
BOND_TYPE	09	HI3 I	L								
BOND_TYPE	09	H21 1	L								
BOND TYPE	C10	H14 1	L								
BOND TYPE	C11	C12 4	1								
DOND TYDE	C12	C13 /	1								
BOND_TIFE		UID 4	±								
BOND_TYPE	C14	HI2 1	L								
BOND_TYPE	C15	C16 1	L								
BOND TYPE	C15	H16 1	L								
BOND TYPE	08	C16 4	1								
BOND TYPE	C16	C17 /	1								
DOND_TIFE	C10 017		1								
BOND_TYPE	CI/	CZU 4	±								
BOND_TYPE	C17	H17 1	L								
BOND_TYPE	C18	C19 4	1								
BOND TYPE	C18	C21 4	1								
BOND TYPE	C19	C20 4	1								
BOND TYPE	C19	$C_{24}$	1								
DOND TITE	C10	C25 1 C25 1	<b>I</b>								
BOND_TIPE	CZU 201		L.								
BOND_TYPE	C21	C22 4	Ŧ								
BOND_TYPE	C21	H20 1	L								
BOND TYPE	09	C22 1	L								
BOND TYPE	C22	C23 4	1								
BOND TYPE	C23	C24 4	1								
DOND TILL	C23	U10 1	-								
BOND_TIFE	023	пту 1 110 1	L								
BOND_TYPE	CZ4 .	HIS I	<u>_</u>								
BOND_TYPE	C25	F1 1	_								
BOND_TYPE	C25	F2 1	L								
BOND TYPE	C25	F3 1	L								
CHI 1 C8	C7	05	HЗ								
PROTON CHT	1 SAM	PLES	21 45	50 55 60	) 65	70 75 -45	-50 -55 -	60 -65	-70 -7	5 165 1	70
175 180 185	5 1 9 0	195 F	CYTRA ()			10 10 10	00 00	00 00		0 100 1	
CUT 2 C0	~ 1 ) U		110								
CHI Z C9	00	00						CO CE			
PROTON_CHI	Z SAM	PLES	21 45	50 55 60	J 65	/0 /5 -45	-50 -55 -	60 -65	-/0 -/	5 165 I	/0
175 180 185	5 190	195 E	extra 0								
CHI 3 C23	C22	09	H21								
CHI 4 N1	C1	C15	C16								
CHT 5 N7	S2	03	C 5								
CHI 6 CA	N7	e2	01								
		22	NT1								
CHI / N/	04	03	IN I								
CHI 8 S2	03	C5	C6								
CHI 9 S2	N7	С4	С3								
CHI 10 04	С9	N4	C11								
CHI 11 03	C5	С6	04								
CHT 12 C1	C15	C16	5 08								
CHT 13 C10	A C20	C25	5 F1								
NDD ADOM N	17 020	020									
NBR_AIOM N	1 - 10	1000									
NBR_RADIUS	15.40	1802			-			_			
ICOOR_INTEF	RNAL	Ν7	Ο.	000000	Ο.	000000	0.000000	N7	S2	01	
ICOOR INTER	RNAL	S2	0.	000000	180.	000000	1.649480	N7	S2	01	
ICOOR INTER	RNAL	01	Ο.	000000	72.	115214	1.437728	S2	N7	01	
ICOOR INTER	RNAL	02	-110.	979907	68.	095120	1,445125	S2	Ν7	01	
TCOOR INTER	NZT.	03	-129	796485	67	884564	1 508898	\$2	N7	02	
TCOOP INTER		C5	125.	072004	50	004304	1 /11561	03	c2	N7	
ICOOK_INIEF		00	4/.	972004	59.	04/20/	1.411301	03	52	IN 7	
ICOOR_INTER	KNAL	60	157.	660576	/0.	/3895/	1.511080	05	03	SZ	
ICOOR_INTEF	RNAL	04	77.	333973	70.	005558	1.402847	C6	C5	03	
ICOOR_INTEF	RNAL	С9	125.	086234	74.	080093	1.413900	04	C6	С5	
ICOOR INTER	RNAL	N4	-109.	502643	70.	720185	1.445332	С9	04	C6	
ICOOR INTER	RNAL	C11	L -150.	229052	54.	143952	1.365802	N4	С9	04	
ICOOR INTER	RNAL	N3	-0	892936	46	223588	1.342216	C11	N4	С9	
TCOOR INTER	NAT.	C10	) -179	432403	59	624923	1 326020	N3	C11	N4	
TCOOD TNUE	NDT	NTO	·	848435	57.	610071	1 331554	C10	N3	C11	
TCOOP INTER			-0.	552052	57.	1201/1	1 2/2000	ULU NO	C10	M3	
ICOOK_INTER	(INAL)	CLU	> U.	JJZUJJ	58.	120141	1.342096	IN Z	CIU	C M	
LCOOR_INTER	NAL	N6	-179.	890730	60.	506917	1.449335	C13	N2	C10	
ICOOR INTER	RNAL	НG	-0.	115371	59.	977458	0.984393	N6	C13	N2	

ICOOR_INTERNAL	H7 17	79.952772	59.961946	0.984831	NG	C13	НG
ICOOR_INTERNAL	C12 1	79.862428	62.184716	1.420651	C13	N2	N6
ICOOR_INTERNAL	N5 -17	79.949517	44.621863	1.328601	C12	C13	N2
ICOOR_INTERNAL	C14 1	79.677558	70.203038	1.324715	N5	C12	C13
ICOOR INTERNAL	H15 -1	79.517871	55.041066	1.032119	C14	N5	C12
ICOOR INTERNAL	H2 -1	79.976464	54.922095	0.984330	N5	C12	C14
ICOOR_INTERNAL	H14 -1	79.959018	61.152494	1.031712	C10	NЗ	N2
ICOOR INTERNAL	C8 12	25.404314	71.733653	1.475916	С9	04	N4
ICOOR INTERNAL	06 9	90.149730	71.799851	1.374530	C8	С9	04
ICOOR INTERNAL	H8 17	79.999645	70.557415	0.969220	06	C8	С9
ICOOR INTERNAL	C7 -12	20.391196	77.527376	1.465575	C8	С9	06
ICOOR INTERNAL	05 15	50.567803	65.743236	1.380198	С7	C8	С9
ICOOR INTERNAL	H3 17	79.981880	70.545702	0.969832	05	С7	С8
ICOOR INTERNAL	H11 11	17.168004	68.989317	1.070413	C7	C8	05
ICOOR INTERNAL	H12 -12	21.158644	63.838599	1.069836	C8	С9	С7
ICOOR INTERNAL	H13 11	17.674596	67.713631	1.070064	С9	04	С8
ICOOR INTERNAL	Н9 -11	19.374097	70.454273	1.069969	C6	C5	04
ICOOR INTERNAL	H4 -11	19.990464	70.450854	1.069592	С5	03	C6
ICOOR INTERNAL	Н5 -11	19.938832	70.434132	1.070190	С5	03	H4
ICOOR INTERNAL	C4 -8	33.828030	58.301695	1.468382	N7	s2	01
ICOOR INTERNAL	C3 17	78.603415	63.816343	1.496095	C4	N7	s2
ICOOR INTERNAL	N1 17	71.714611	59.715820	1.309092	C3	C4	N7
ICOOR INTERNAL	C1 1 <sup>-</sup>	79.404452	66.574660	1.362844	N1	C3	C4
ICOOR INTERNAL	C15 1	79.223421	54.664545	1.476648	C1	N1	C3
TCOOR INTERNAL	C16 -1	79.989679	56.710153	1.346762	C15	C1	N1
ICOOR INTERNAL	08	0.912521	59.265165	1.353938	C16	C15	C1
ICOOR INTERNAL	C18 1	79.613843	56.700286	1.353045	08	C16	C15
ICOOR INTERNAL	C19	0.696119	58,989698	1.419737	C18	08	C16
ICOOR INTERNAL	C20 -	-0.534929	62.229493	1.516594	C19	C18	08
ICOOR INTERNAL	C17 -	-0.014746	61.919117	1.352467	C20	C19	C18
ICOOR INTERNAL	H17 -1	79 863883	59 795042	1 088156	C17	C20	C19
ICOOR INTERNAL	C25 -1	79 760539	53 572574	1 525937	C20	C19	C17
ICOOR INTERNAL	F1 -	-0 152786	65 152910	1 374488	C25	C20	C19
ICOOR INTERNAL	F2 -12	20 702945	70 924488	1 383259	C25	C20	F1
ICOOR INTERNAL	F3 -11	18 504269	70 882734	1 383434	C25	C20	F2
ICOOR INTERNAL	C24 -1	79 969607	62 368500	1 414553	C19	C18	C20
ICOOR INTERNAL	C23	0 083722	59 067642	1 398551	C24	C19	C18
ICOOR INTERNAL	C22	0 123564	59 352531	1 393135	C23	C24	C19
ICOOR INTERNAL	C21 -	-0 006879	60 580877	1 397258	C22	C23	C24
ICOOR INTERNAL	H20 1	79 995074	60 167720	1 083846	C21	C22	C23
ICOOR INTERNAL	09 -17	79 830419	60 331140	1 346965	C22	C23	C21
ICOOR INTERNAL	H21 1	79 547800	57 851533	0 967795	09	C22	C23
ICOOR INTERNAL	H19 -17	79 995294	60 475787	1 083563	C23	C24	C22
ICOOR INTERNAL	H18 1	79 968998	56 552726	1 071404	C24	C19	C23
ICOOR INTERNAL	H16 -17	79 899585	62 673003	1 087086	C15	C1	C16
ICOOR INTERNAL	S1 _1"	79 809293	71 177075	1 654766	C1	N1	C15
ICOOR INTERNAL	C2	0 06109293	84 158025	1 751110	S1	C1	N1
TCOOR INTERNAL	UL _1	79 547396	51 165915	1 0301/5	C2	Q1	C1
ICOOR INTERNAL	07 17	79 981870	56 614562	1 227206	C4	N7	C A
TCOOR INTERNAL	U10 1	79 981530	60 81/007	T.22/200	U4 N7	G Q	C3
TCOOK INTERNAL	L VIN	12.204330	00.01499/	0.904202	TN /	54	64

The Fluc structure was used as input to the RosettaMatch protocol.<sup>16</sup> This algorithm identifies potential binding modes of input ligands based on user-defined constraints. A binding interaction is considered a "hit" if the ligand atoms do not collide with the protein backbone atoms. The following command line was used to call the RosettaMatch application.

```
<Path to>/Rosetta/main/source/bin/match.linuxgccrelease -s <input_file> @<Path
to>//general_match.flags -match:scaffold_active_site_residues_for_geomcsts <Path
to>/pos_file <Path to>/CouLuc-1_ligand.flags
Where the contents of the pos file was as follows.
```

N\_CST 1 1: 308 The contents of the constraint file were as follows.

```
CST::BEGIN
NATIVE
               ATOM MAP: 1 atom name: 07 C4 C3
  TEMPLATE::
  TEMPLATE:: ATOM MAP: 1 residue3: LCC/LCD/LCE
  TEMPLATE:: ATOM MAP: 2 atom name: N CA C ,
  TEMPLATE:: ATOM MAP: 2 residue1: G
  TEMPLATE:: ATOM MAP: 2 is backbone
  CONSTRAINT:: distanceAB: 4.30 1.50 80.0 1
                                                            1
  CONSTRAINT:: angle_A: 135.3 10.0 10.0 360. 1
 CONSTRAINT::angle_B:43.610.010.0360.1CONSTRAINT::torsion_A:10.710.010.0360.1CONSTRAINT::torsion_AB:-160.710.010.0360.1CONSTRAINT::torsion_B:-134.110.010.0360.1
  ALGORITHM INFO:: match
     CHI STRATEGY:: CHI 1 EX THREE THIRD STEP STDDEVS
     CHI STRATEGY:: CHI 2 EX THREE THIRD STEP STDDEVS
  ALGORITHM INFO::END
CST::END
```

The contents of the CouLuc-1 ligand.flags files were as follows.

```
-extra_res_fa <Path to>/CouLuc-1_ligand.params
-match:geometric_constraint_file <Path to>/CouLuc-1_ligand.cst
-match:lig_name_LCC/LCD/LCE
```

The contents of the general match.flags files was as follows.

```
-packing
 -ex1
 -ex2
 -ex2aro
 -exlaro
-extrachi cutoff 0
-use input sc true
-database <Path to>/Rosetta/main/database/
-match:filter colliding upstream residues
-match:filter_upstream_downstream_collisions
-match:upstream residue collision tolerance 0.95
-match:updown collision tolerance 0.3
-match::bump tolerance \overline{0.3}
-match grouper SameSequenceAndDSPositionGrouper
-match:grouper downstream rmsd 0.5
-match: euclid \overline{b}in size 0.\overline{5}
-match:euler bin size
                         5.0
-output format PDB
-exclude patches N acetylated
-consolidate matches 1
-output matches per group 1
-output matchres only false
-enumerate ligand rotamers
-only enumerate non match redundant ligand rotamers
-out::file::output virtual
```

The pdb files generated in the matching run were then used as inputs for RosettaDesign calculations. The RosettaDesign algorithm is used to re-sculpt the pocket surrounding the docked luciferin analogue in order to remove clashing side chains and introduce new, productive

interactions with the ligand. The RosettaDesign application was called with the following command line:

```
<Path to>/Rosetta/main/source/bin/rosetta_scripts.linuxgccrelease -s <input_file> -
parser:protocol <Path to>/enzdes.xml -nstruct 1 -jd2:ntrials 1 -database <Path
to>/Rosetta/main/database/ @<Path to>/CouLuc-1 ligand.flags @<Path to>/general.flags
```

The contents of the RosettaDesign general.flags file was as follows:

```
-run::preserve_header
-enzdes::minimize_ligand_torsions 7.0
-enzdes::detect design interface
-unmute protocols.enzdes.EnzRepackMinimize
-packing::use input sc
-packing::extrachi_cutoff 1
-packing::ex1
-packing::ex2
-linmem ig 10
-in:ignore unrecognized res
-ligand::old estat
-jd2:enzdes out
-nblist autoupdate
-score:weights <Path to>/Rosetta/main/database/scoring/weights/ref2015.wts
-enzdes::bb min allowed dev 0.05
-no his his pairE
```

The contents of the RosettaDesign enzdes.xml file was as follows:

<ROSETTASCRIPTS>

```
<TASKOPERATIONS>
              <DetectProteinLigandInterface name="dsgn cuts on" cut1="6" cut2="8"</pre>
cut3="10" cut4="12" design="1"/>
              <DetectProteinLigandInterface name="dsgn cuts off" cut1="6" cut2="8"</pre>
cut3="10" cut4="12" design="0"/>
              <RestrictResiduesToRepacking name="pack only" residues="210,221"/>
       </TASKOPERATIONS>
       <SCOREFXNS>
              <ScoreFunction name="ref2015" weights="ref2015.wts"/>
       </SCOREFXNS>
       <MOVERS>
              #Add constraints to file
              AddOrRemoveMatchCsts name="addcst" cst instruction=add new
cstfile="../inputs/FAB.cst"/>
              <AddOrRemoveMatchCsts name="addcst" cst_instruction="add_new"/>
<AddOrRemoveMatchCsts name="rmvcst" cst_instruction="remove"</pre>
keep covalent="1"/>
              <AddOrRemoveMatchCsts name="addprg" cst instruction=add pregenerated/>
              #Optimize the pose per the cst file
              <EnzRepackMinimize name="cstopt" scorefxn_minimize="ref2015" cst_opt="1"
design="0" repack only="0" fix catalytic="0" minimize rb="1" minimize bb="1"
minimize sc="1" minimize liq="1" min in stages="1" cycles="1"
task operations="dsgn cuts off"/>
              #Design and repacking around the catalytic residues; keep the catalytic
residues fixed in this instance.
              <EnzRepackMinimize name="dsgn" scorefxn_minimize="ref2015" cst_opt="0"</pre>
design="1" repack_only="0" fix_catalytic="1" minimize_rb="1" minimize_bb="1"
minimize sc="1" minimize lig="1" min in stages="1" backrub="0" cycles="1"
task operations="dsgn cuts on, pack only"/>
```

```
#Minimize after each design.
             <EnzRepackMinimize name="min" scorefxn minimize="ref2015" cst opt="0"</pre>
design="0" repack only="0" fix catalytic="1" minimize rb="1" minimize bb="1"
minimize sc="1" minimize lig="1" min in stages="1" backrub="0" cycles="1"
task operations="dsgn cuts off"/>
             #Perform a final repacking step.
             <EnzRepackMinimize name="rpkmin" scorefxn minimize="ref2015" cst opt="0"</pre>
design="0" repack only="1" fix catalytic="0" minimize rb="1" minimize bb="1"
minimize sc="1" minimize lig="0" min in stages="1" backrub="0" cycles="1"
task operations="dsqn cuts off"/>
             #Monte Carlo movers for each step in the enzdes process (helps to
generate )
             <GenericMonteCarlo name="multi cstopt" mover name="cstopt"
scorefxn name="ref2015" trials="10" sample type="low" temperature="0.6" drift="1"
recover low="1" preapply="0"/>
       </MOVERS>
       <PROTOCOLS>
             <Add mover_name="addcst"/>
             <Add mover_name="multi_cstopt"/>
             <Add mover_name="dsgn"/>
             <Add mover name="min"/>
             <Add mover name="dsgn"/>
             <Add mover name="min"/>
             <Add mover name="dsgn"/>
             <Add mover name="min"/>
             Add mover=rmvcst/>
             Add mover=rpkmin/>
             Add mover=des min/>
             Add mover=des min/>
             Add mover=des min/>
             Add mover name="rmvcst"/>
             Add mover_name="rpkmin"/>
             Add mover=finmin_rpkmin/>
       </PROTOCOLS>
```

```
</ROSETTASCRIPTS>
```

#### Synthetic materials and methods

Unless stated otherwise, reactions were conducted in oven-dried glassware under an atmosphere of nitrogen using anhydrous solvents. All commercially obtained reagents were used as received. Flash column chromatography was performed using reversed phase (100 Å, 20-40 micron particle size, RediSep® Rf Gold® Reversed-phase C18 or C18Aq) on a CombiFlash® Rf 200i (Teledyne Isco, Inc.). High-resolution LC/MS analyses were conducted on a Thermo-Fisher LTQ-Orbitrap-XL hybrid mass spectrometer system with an Ion MAX API electrospray ion source in negative ion mode. Analytical LC/MS was performed using a Shimadzu LCMS-2020 Single Quadrupole utilizing a Kinetex 2.6 µm C18 100 Å (2.1 x 50 mm) column obtained from Phenomenex, Inc. Runs employed a gradient of  $0 \rightarrow 90\%$  MeCN/0.1% aqueous formic acid over 4.5 min at a flow rate of 0.2 mL/min. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on Bruker spectrometers (at 400 or 500 MHz or at 100 or 125 MHz) and are reported relative to deuterated solvent signals. Data for <sup>1</sup>H NMR spectra are reported as follows: chemical shift ( $\delta$  ppm), multiplicity, coupling constant (Hz), and integration. Data for <sup>13</sup>C NMR spectra are reported in terms of chemical shift. Absorption curves were obtained on a Shimadzu UV-2550 spectrophotometer operated by UVProbe 2.32 Fluorescence traces were recorded on a PTI QuantaMaster steady-state software. spectrofluorometer operated by FelixGX 4.2.2 software, with 5 nm excitation and emission slit widths, 0.1 s integration rate, and enabled emission correction. Data analysis and curve fitting were performed using MS Excel 2019 and GraphPad Prism 8.

#### Synthetic procedures



#### General procedure for the synthesis of nitrile (2)

To a solution of CH<sub>3</sub>CN (8.0 mmol, 4.0 eq) in THF (20 mL) was added *n*-BuLi (8.0 mmol, 2.5 M, 4.0 eq) at -78 °C. The solution was stirred at -78 °C 10 minutes, after which a solution of coumarin (1) (2.0 mmol, 1.0 eq) in 5 mL of THF was added slowly. The reaction was stirred at -78 °C for 10-15 min and quenched with 15 mL aqueous NH<sub>4</sub>Cl solution. The mixture was warmed to room temperature and extracted with EtOAc and concentrated. To the crude oil was added 125 mL of 0.5 M HCl and stirred vigorously for 1-4 h. The precipitate was extracted with EtOAc, dried Na<sub>2</sub>SO<sub>4</sub> and concentrated to give nitrile **2** as a mixture of isomers. Based on <sup>1</sup>H NMR spectroscopic analysis, the resulting product was typically >90% pure and was typically used in the next step without further purification. Silica gel column chromatography could be performed using EtOAc/hexanes to obtain high purity material (>95%).



#### (Z/E)-2-(7-Dimethylamino)-4-(trifluoromethyl)-2H-chromen-2-ylidene)acetonitrile (2a).

Following general procedure using commercial 7-(dimethylamino)-4the (trifluoromethyl)coumarin (1a) (514 mg, 2.0 mmol). Purification by flash chromatography on silica gel (hexanes/EtOAc, 0% to 20%) afforded 2a as an orange solid (358 mg, 64% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz, compound exists as a mixture of isomers, Z-isomer denoted by \*, Eisomer denoted by §)  $\delta$  7.32 – 7.26 (m, 1H\*, 1H§), 6.85 (s, 1H§), 6.50 – 6.47 (m, 2H\*, 1H§), 6.38 (s, 1H\*), 6.33 (d, J = 2.6 Hz, 1H<sup>§</sup>), 4.78 (s, 1H<sup>§</sup>), 4.48 (s, 1H\*), 3.05 (s, 6H\*), 3.04 (s, 6H<sup>§</sup>); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  164.1<sup>§</sup>, 162.6<sup>\*</sup>, 154.6<sup>§</sup>, 153.1<sup>\*</sup>, 131.7 (q, J = 33.0 Hz)<sup>§</sup>, 131.1 (q, J = 33.0 \text{ Hz})<sup>§</sup>, 131.1 (q, J = 33.0 Hz)<sup>§</sup>, 131.1 (q, J = 33.0 \text{ Hz})<sup>§</sup>, 131. 33.0 Hz)\*, 125.8 (q, J = 2.2 Hz)<sup>§</sup>, 125.6 (q, J = 2.2 Hz)\*, 122.3 (q, J = 272.8 Hz)<sup>§</sup>, 122.2 (q, J = 272.8 Hz)<sup>§</sup>, 122.8 Hz)<sup>§</sup>, 122.2 ( 272.6 Hz)\*, 117.7<sup>§</sup>, 116.9\*, 112.6 (q, J = 6.3 Hz)\*, 111.2 (q, J = 6.3 Hz)<sup>§</sup>, 108.7<sup>§</sup>, 108.7\*, 103.4\*, 103.3<sup>§</sup>, 98.7<sup>\*</sup>, 98.1<sup>§</sup>, 73.6<sup>§</sup>, 72.3<sup>\*</sup>, 40.2<sup>\*</sup>, 40.2<sup>§</sup>; <sup>19</sup>F NMR (CDCl<sub>3</sub>, 377 MHz) δ -64.5<sup>§</sup>, -64.6<sup>\*</sup>; HRMS (ESI) calculated for Z-isomer C<sub>14</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O (M+H)<sup>+</sup> 290.0896, observed 290.0900; Eisomer C<sub>14</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O (M+H)<sup>+</sup> 290.0896, observed 290.0901.



#### (Z/E)-2-(7-Amino-4-(trifluoromethyl)-2H-chromen-2-ylidene)acetonitrile (2b).

Following the general procedure using commercial 7-amino-4-(trifluoromethyl)coumarin (**1b**) (458 mg, 2.0 mmol). Purification by flash chromatography on silica gel (hexanes/EtOAc, 0% to 30%) afforded **2b** as an orange solid (308 mg, 61% yield). <sup>1</sup>H NMR (CD<sub>3</sub>CN, 400 MHz, compound exists as a mixture of isomers, *Z*-isomer denoted by \*, *E*-isomer denoted by <sup>§</sup>)  $\delta$  7.24 – 7.18 (m, 1H\*, 1H<sup>§</sup>), 6.77 (dd, *J* = 2.4, 1.2 Hz, 1H<sup>§</sup>), 6.62 (dd, *J* = 2.4, 1.2 Hz, 1H\*), 6.51 – 6.49 (m, 1H\*, 1H<sup>§</sup>), 6.44 (d, *J* = 2.3 Hz, 1H\*), 6.37 (d, 1H<sup>§</sup>), 5.00 – 4.92 (m, 2H\*, 2H<sup>§</sup>), 4.91 (s, 1H<sup>§</sup>), 4.73 (s, 1H\*); <sup>13</sup>C NMR (CD<sub>3</sub>CN, 125 MHz)  $\delta$  164.6<sup>§</sup>, 163.3\*, 155.6<sup>§</sup>, 155.4\*, 153.7<sup>§</sup>, 153.5\*, 131.8 (q, *J* = 32.1 Hz)<sup>§</sup>, 130.7 (q, *J* = 32.1 Hz)\*, 126.8 (q, *J* = 2.2 Hz)<sup>§</sup>, 126.6 (q, *J* = 2.2 Hz)\*, 123.3 (q, *J* = 273.7 Hz)<sup>§</sup>, 123.3 (q, *J* = 273.5 Hz)\*, 118.1<sup>§</sup>, 117.3\*, 114.8 (q, *J* = 6.5 Hz)\*, 112.2 (q, *J* = 6.5 Hz)<sup>§</sup>, 112.1\*, 112.0<sup>§</sup>, 104.8\*, 104.5<sup>§</sup>, 101.1\*, 100.9<sup>§</sup>, 74.7<sup>§</sup>, 73.5\*; <sup>19</sup>F NMR (CD<sub>3</sub>CN, 377 MHz)  $\delta$  - 64.6\*, -64.7<sup>§</sup>; HRMS (ESI) calculated for C<sub>12</sub>H<sub>8</sub>F<sub>3</sub>N<sub>2</sub>O (M+H)<sup>+</sup> 253.0583, observed 253.0582.



#### (Z/E)-2-(7-Hydroxy-4-(trifluoromethyl)-2H-chromen-2-ylidene)acetonitrile (2c).

Following the general procedure using commercial 7-hydroxy-4-(trifluoromethyl)coumarin (1c) (460 mg, 2.0 mmol). Purification by flash chromatography on silica gel (hexanes/EtOAc, 0% to 50%) afforded 2c as a yellow solid (354 mg, 70% yield). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz, compound exists as a mixture of isomers, *Z*-isomer denoted by \*, *E*-isomer denoted by <sup>§</sup>)  $\delta$  7.37 – 7.31 (m, 1H\*, 1H<sup>§</sup>), 6.93 – 6.92 (m, 1H<sup>§</sup>), 6.86 – 6.84 (m, 1H\*), 6.71 – 6.66 (m, 2H\*, 1H<sup>§</sup>), 6.60 (d, *J* = 2.4 Hz, 1H<sup>§</sup>), 5.11 (s, 1H<sup>§</sup>), 4.96 (s, 1H\*); <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100 MHz)  $\delta$  164.7<sup>§</sup>, 163.5\*, 163.4<sup>§</sup>, 163.1\*, 155.9<sup>§</sup>, 155.6\*, 132.3 (q, *J* = 323.0 Hz)<sup>§</sup>, 131.1 (q, *J* = 323.0 Hz)\*, 127.6\*, 127.6<sup>§</sup>, 127.2 (q, *J* = 1.8 Hz)<sup>§</sup>, 127.0 (q, *J* = 1.8 Hz)\*, 124.9\*, 124.8<sup>§</sup>, 122.1\*, 122.1<sup>§</sup>, 117.9\*, 117.1 (q, *J* = 6.5 Hz)\*, 117.0<sup>§</sup>, 114.3 (q, *J* = 6.4 Hz)<sup>§</sup>, 114.0<sup>§</sup>, 114.0\*, 107.6\*, 107.3<sup>§</sup>, 104.1<sup>§</sup>, 104.0\*, 75.9<sup>§</sup>, 74.4\*; <sup>19</sup>F NMR (CD<sub>3</sub>OD, 377 MHz)  $\delta$  -66.1<sup>§</sup>, -66.2\*; HRMS (ESI) calculated for C<sub>12</sub>H<sub>5</sub>F<sub>3</sub>NO<sub>2</sub> (M–H)<sup>-</sup> 252.0278, observed 252.0270.



#### General procedure for the synthesis of CouLuc-1-R

To a microwave vial containing nitrile (2) (0.15 mmol, 1.0 eq), D-cysteine hydrochloride monohydrate (0.23 mmol, 1.5 eq) and NaHCO<sub>3</sub> (0.60 mmol, 4.0 eq) was added N<sub>2</sub>-sparged EtOH (1.5 mL). The suspension was heated at 85 °C under N<sub>2</sub> and monitored by LC/MS. After 3-5 days the consumption of 2 is greater than 75%. The reaction mixture was cooled to room temperature and EtOH was evaporated under vacuum. The crude solid was triturated with Et<sub>2</sub>O (3 x 5 mL), acidified to pH 1.0, filtered and wash with cold water (3 x 5 mL). The crude mixture was purified directly by reversed phase chromatography (C<sub>18</sub>, 0-100% MeOH/water). The solvent was removed *in vacuo* to afford **CouLuc-1-R**.



#### (Z)-2-((7-(Dimethylamino)-4-(trifluoromethyl)-2H-chromen-2-ylidene)methyl)-4,5-dihydrothiazole-4-carboxylic acid (CouLuc-1-NMe<sub>2</sub>).

Following the general procedure using **2a** (42 mg, 0.15 mmol), **CouLuc-1-NMe**<sub>2</sub> was obtained as a red solid (23 mg, 40% yield). <sup>1</sup>H NMR (CD<sub>3</sub>OD + TFA- $d_1$ , 500 MHz)  $\delta$  7.56 – 7.53 (m, 1H), 6.93 (s, 1H), 6.89 (dd, J = 9.3, 2.6 Hz, 1H), 6.76 (d, J = 2.6 Hz, 1H), 6.18 (s, 1H), 5.16 (dd, J = 9.4, 5.6 Hz, 1H), 4.00 – 3.90 (m, 2H), 3.14 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO- $d_6$  + TFA- $d_1$ )  $\delta$  186.3, 179.5, 173.0, 164.0, 163.1, 143.1 (q, J = 32.5 Hz), 135.0, 131.6 (q, J = 275.6 Hz), 128.3, 122.4 (q, J = 6.1 Hz), 121.1, 112.9, 106.7, 102.8, 72.0, 43.4; <sup>19</sup>F NMR (DMSO- $d_6$ , 377 MHz)  $\delta$  - 63.4; HRMS (ESI) calculated for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S (M+H)<sup>+</sup> 385.0828, observed 385.0833.



(Z)-2-((7-Amino-4-(trifluoromethyl)-2H-chromen-2-ylidene)methyl)-4,5-dihydro-thiazole-4carboxylic acid (CouLuc-1-NH<sub>2</sub>).

Following the general procedure using **2b** (37 mg, 0.15 mmol), **CouLuc-1-NH**<sub>2</sub> was obtained as an orange solid (28 mg, 52% yield). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  7.09 – 7.02 (m, 1H), 6.87 (s, 1H), 6.45 – 6.38 (m, 2H), 6.14 (s, 2H), 5.94 (s, 1H), 4.96 (t, *J* = 9.0 Hz, 1H), 3.49 (dd, *J* = 11.1, 9.5 Hz, 1H), 3.41 (dd, *J* = 11.1, 8.5 Hz, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  172.3, 162.5, 153.8, 152.8, 152.7, 126.5 (q, *J* = 30.6 Hz), 124.9, 122.5 (q, *J* = 271.9 Hz), 115.9 (q, *J* = 6.3 Hz), 110.3, 102.2, 101.8, 99.3, 76.2, 32.2; <sup>19</sup>F NMR (DMSO-*d*<sub>6</sub>, 377 MHz)  $\delta$  -63.4; HRMS (ESI) calculated for C<sub>15</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S (M+H)<sup>+</sup> 357.0515, observed 357.0523.



#### (Z)-2-((7-hydroxy-4-(trifluoromethyl)-2H-chromen-2-ylidene)methyl)-4,5-dihydro-thiazole-4carboxylic acid (CouLuc-1-OH).

Following the general procedure using **2c** (38 mg, 0.15 mmol), **CouLuc-1-OH** was obtained as an orange solid (24 mg, 45% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD + TFA- $d_1$ )  $\delta$  7.63 – 7.61 (m, 1H), 7.25 (s, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.97 (dd, J = 8.9, 2.4 Hz, 1H), 6.32 (s, 1H), 5.29 (dd, J = 9.8, 5.7 Hz, 1H), 4.06 (dd, J = 12.1, 9.8 Hz, 1H), 4.01 (dd, J = 12.0, 5.7 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD + TFA- $d_1$ )  $\delta$  180.3, 170.6, 165.3, 164.7, 156.1, 136.4 (q, J = 33.2 Hz). 127.9 (q, J = 2.4 Hz), 123.2 (q, J = 272.3 Hz), 116.8 (q, J = 5.9 Hz), 116.4, 108.4, 104.3, 64.4, 35.1; <sup>19</sup>F NMR (CD<sub>3</sub>OD + TFA- $d_1$ , 377 MHz)  $\delta$  -65.5; HRMS (ESI) calculated for C<sub>15</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>4</sub>S (M+H)<sup>+</sup> 358.0355, observed 358.0358.

#### Synthesis of CouLuc-1-NMe2 with chromatography-free procedure



To a reaction flask containing nitrile (2a) (1.25 g, 4.49 mmol), D-cysteine hydrochloride monohydrate (1.18 g, 6.73 mmol) and NaHCO<sub>3</sub> (1.51 g, 17.94 mmol) was N<sub>2</sub>-sparged EtOH (45 mL) was heated at 85 °C under N<sub>2</sub>. After heating for 3 days the EtOH was evaporated under vacuum. The yellow solid was triturated with Et<sub>2</sub>O (3 x 20 mL), acidified to pH 1.0 with 1M HCl to give a red solid that was separated by centrifugation and the supernatant was discarded. The precipitates were suspended in 15 mL water and then centrifuged. The washing process was repeated twice. The precipitate was dried under reduced pressure to afford CouLuc-1-NMe<sub>2</sub> as a red solid (468 mg, 27% yield) to provide high purity material by NMR (>95%).

#### References

- Tinberg, C. E.; Khare, S. D.; Dou, J.; Doyle, L.; Nelson, J. W.; Schena, A.; Jankowski, W.; Kalodimos, C. G.; Johnsson, K.; Stoddard, B. L.; Baker, D. Computational design of ligand-binding proteins with high affinity and selectivity. *Nature* 2013, *501*, 212.
- 2. Zanghellini, A.; Jiang, L.; Wollacott, A. M.; Cheng, G.; Meiler, J.; Althoff, E. A.; Röthlisberger, D.; Baker, D. New algorithms and an in silico benchmark for computational enzyme design. *Protein Sci.* **2006**, *15*, 2785.
- 3. Studier, F. W. Protein production by auto-induction in high-density shaking cultures. *Protein Expr. Purif.* **2005**, *41*, 207.
- 4. Rathbun, C. M.; Porterfield, W. B.; Jones, K. A.; Sagoe, M. J.; Reyes, M. R.; Hua, C. T.; Prescher, J. A. Parallel screening for rapid identification of orthogonal bioluminescent tools. *ACS Cent. Sci.* **2017**, *3*, 1254.
- 5. Jones, K. A.; Porterfield, W. B.; Rathbun, C. M.; McCutcheon, D. C.; Paley, M. A.; Prescher, J. A. Orthogonal luciferase–luciferin pairs for bioluminescence imaging. *J. Am. Chem. Soc.* **2017**, *139*, 2351.
- 6. Rathbun, C. M.; Ionkina, A. A.; Yao, Z.; Jones, K. A.; Porterfield, W. B.; Prescher, J. A. Rapid multicomponent bioluminescence imaging via substrate unmixing. *ACS Chem. Biol.* **2021**, *16*, 682.
- 7. Zhang, B. S.; Jones, K. A.; McCutcheon, D. C.; Prescher, J. A. Pyridone luciferins and mutant luciferases for bioluminescence imaging. *ChemBioChem* **2018**, *19*, 470–477.
- 8. Harwood, K. R.; Mofford, D. M.; Reddy, G. R.; Miller, S. C. Identification of mutant firefly luciferases that efficiently utilize aminoluciferins. *Chem. Biol.* **2011**, *18*, 1649.

- 9. Belsare, K. D.; Andorfer, M. C.; Cardenas, F. S.; Chael, J. R.; Park, H. J.; Lewis, J. C. A simple combinatorial codon mutagenesis method for targeted protein engineering. *ACS Synth. Biol.* **2017**, *6*, 416.
- 10. Yao, Z.; Zhang, B. S.; Steinhardt, R. C.; Mills, J. H.; Prescher, J. A. Multicomponent bioluminescence imaging with a  $\pi$ -extended luciferin. *J. Am. Chem. Soc.* **2020**, *142*, 14080.
- 11. Gammon, S. T.; Leevy, W. M.; Gross, S.; Gokel, G. W.; Piwnica-Worms, D. Spectral unmixing of multicolored bioluminescence emitted from heterogeneous biological sources. *Anal. Chem.* **2006**, *78*, 1520.
- Alford, R. F.; Leaver-Fay, A.; Jeliazkov, J. R.; O'Meara, M. J.; DiMaio, F. P.; Park, H.; Shapovalov, M. V.; Renfrew, P. D.; Mulligan, V. K.; Kappel, K.; Labonte, J. W.; Pacella, M. S.; Bonneau, R.; Bradley, P.; Dunbrack, R. L.; Das, R.; Baker, D.; Kuhlman, B.; Kortemme, T.; Gray, J. J. The Rosetta all-atom energy function for macromolecular modeling and design. *J. Chem. Theory Comput.* **2017**, *13*, 3031.
- 13. Nivón, L. G.; Moretti, R.; Baker, D. A pareto-optimal refinement method for protein design scaffolds. *PLoS One* **2013**, *8*, e59004.
- Hanwell, M. D.; Curtis, D. E.; Lonie, D. C.; Vandermeersch, T.; Zurek, E.; Hutchison, G. R. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. *J. Cheminformatics* 2012, *4*, 17.
- 15. Rappe, A. K.; Casewit, C. J.; Colwell, K. S.; Goddard, W. A.; Skiff, W. M. UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. *J. Am. Chem. Soc.* **1992**, *114*, 10024–10035.
- 16. Richter, F.; Leaver-Fay, A.; Khare, S. D.; Bjelic, S.; Baker, D. De novo enzyme design using Rosetta3. *PLoS One* **2011**, *6*, e19230.

# NMR Spectra







10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210
											f1 (ppm)											







																								-
10	0	-	10	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210	
												f1 (ppm)												













																	· · ·					_	-
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100 f1 (ppm)	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210	





![](_page_56_Figure_0.jpeg)

![](_page_57_Figure_0.jpeg)

![](_page_58_Figure_0.jpeg)

![](_page_59_Figure_0.jpeg)